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ABSTRACT 
Two newly found polyomaviruses are related to human skin diseases; Merkel cell 
polyomavirus (MCPyV), identified in Merkel cell carcinomas (MCC) is believed to be an 
etiologic factor in the pathogenesis of MCC; trichodysplasia spinulosa-associated 
polyomavirus (TSPyV), discovered in TS lesions, has an apparently causative role in this 
rare skin disease. To investigate their seroprevalence and possible clinical significance, we 
have developed for these two polyomaviruses comprehensive serodiagnostic methods and 
studied the occurrence of antibodies to these viruses, the quality of immune responses, 
diagnostic criteria, and possible disease associations. In addition, the thesis aims at 
searching for factors that cause false results in biotinylation-based antiviral IgM enzyme 
immunoassays (EIAs).  
For MCPyV and TSPyV, we developed EIAs for virus-specific IgG, IgM and IgG 
avidity, by using the major capsid protein VP1 expressed in insect cells as self-assembled 
into virus-like particles. To determine seroprevalence and seroconversion rates, virus-
specific IgG antibody assays were applied to examine serum samples from adults and 
three groups of children less than 13 years of age. In the first two children s´ groups, 
children underwent initial and 3-8-year follow-up sampling. In the third group, children 
were followed clinically from birth until 13 years of age, and from each such child 
consecutive serum samples were obtained. Among Finnish adults, the seroprevalence for 
MCPyV was 58% and for TSPyV 70%. Among Finnish children between 1-13 years of 
age, the seroprevalence for MCPyV were determined at 9-45%, with seroconversion rates 
of 16-33% during the 3-8-year follow-up, while for TSPyV the seroprevalence was 5-39%, 
with seroconversion rates of 30-45%. Among 144 children followed from birth up to 13 
years, 31% and 27% had IgG seroconversion to MCPyV and to TSPyV, respectively. 
These data indicate that MCPyV and TSPyV circulate widely in the general population, 
and that primary infections by these two viruses occur extensively in childhood with the 
first exposures taking place at young age. 
We then investigated whether in children primary infections with these two viruses 
were associated with any symptoms or signs. For each virus, EIAs for antiviral IgG, IgM 
and IgG avidity, along with quantitative PCR were employed on consecutive serum 
samples from the seroconverting children in the third children s´ group. At the time of IgG 
seroconversion, additional infection markers (IgM response and/or low-avidity IgG) were 
found to be present in 62% of the MCPyV seroconverters, and in 82% of the TSPyV 
seroconverters. Comparing clinical events during the seroconversion intervals with those 
during the previous and subsequent intervals, we found that with neither virus primary 
infection was significantly associated with symptoms or signs of any infection-related 
illness. These observations imply that in childhood primary infections with MCPyV or 
TSPyV are in general asymptomatic.  
To improve the quality of serodiagnostic assays, we looked for factors causing false 
IgM reactivities in IgM assays in which captured virus-specific IgM antibodies are 
detected by biotinylated viral antigens bound to horseradish peroxidase conjugated 
streptavidin. Employed as negative control for our MCPyV IgM EIA, one adult serum 
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sample exhibited IgM reactivity against the biotinylated viral antigen, but did not show 
reactivity against the non-biotinylated one. This observation pointed to the occurrence of 
anti-biotin IgM in human blood, causing false-positive results in biotinylation-based 
antiviral IgM assays. To investigate the prevalence of biotin-specific IgM antibodies in the 
general population, we developed an indirect EIA for biotin IgM, and found these 
antibodies to be present in 3% of adults regardless of age but rarely in children. Adverse 
effects of the biotin IgM were examined with a variety of biotinylation-based antiviral 
IgM assays. Interestingly, soluble biotin failed to bind the IgM and streptavidin/avidin 
simultaneously, pointing to the possibility that the IgM and streptavidin/avidin share the 
same binding site on biotin. The affinities of biotin IgM antibodies were determined at a 
range of 10
-3
 to 10
-4 
mol/L. These findings provide new information on biotinylation-
based immunoassays, and open new insights into anti-vitamin immune responses. 
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INTRODUCTION 
Polyomaviruses belong to the family Polyomaviridae, consisting of small non-enveloped 
viruses with a double-stranded, covalently closed circular DNA genome (1). The family 
name originates from Greek, “poly” meaning “many” and “oma”, meaning “tumor”. A 
number of mammalian and avian polyomaviruses have been identified, however, with 
each virus species demonstrating a narrow host range (1). In contrast, the polyomaviruses 
can experimentally transform non-permissive cells and induce tumors in their non-natural 
hosts (2-5). So far, twelve human polyomaviruses (HPyVs) have been found, and ten of 
them are discoveries of the past six years. Among these recently found HPyVs, two are 
found to be associated with human skin diseases: Merkel cell polyomavirus (MCPyV or 
MCV) with Merkel cell carcinoma (MCC) and trichodysplasia spinulosa-associated 
polyomavirus (TSPyV or TSV) with trichodysplasia spinulosa (TS) disease.  
In 2008, MCPyV was found in MCC, an uncommon and aggressive skin cancer, and 
subsequently the virus was shown to be present in 30%-100% of MCCs around the world 
(6, 7). The virus DNA is integrated into the genome of tumor cells and harbors specific 
mutations that eliminate viral replication capacity, but retain their oncogenicity, strongly 
suggesting that the virus is a pathogenetic factor in MCC (6, 8). In 2010, TSPyV was 
discovered in TS lesions of a heart transplant patient, with an apparent causal relation of 
the virus with this rare skin disease that is predominant in immunosuppression (9). 
Moreover, by analysis of all available TS cases worldwide, an active TSPyV infection was 
demonstrated to be associated with TS pathogenesis (10).  
As MCPyV and TSPyV are recent discoveries, information on their impact beyond 
MCC and TS is just beginning to accumulate. The purposes of this thesis are to develop 
for these two recently found HPyVs comprehensive serodiagnostic methods, and to 
disclose the occurrence and possible disease associations of these two HPyVs.   
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REVIEW OF THE LITERATURE 
1. Overview of human polyomaviruses 
HPyVs comprise twelve members (Table 1). JC polyomavirus (JCPyV or JCV) and BK 
polyomavirus (BKPyV or BKV) are the classical members known to infect humans (JC 
and BK stand for the initials of the patients from whom the viruses were first detected). In 
1971, the former was identified in the brain tissue of a progressive multifocal 
leukoencephalopathy (PML) patient (11), and the latter in the urine of a nephropathic 
kidney transplant recipient (12). Since 2007, many additional HPyVs have been found. KI 
polyomavirus (KIPyV) and WU polyomavirus (WUPyV) (KI stands for Karolinska 
Institute and WU for Washington University) were in 2007 identified in the 
nasopharyngeal aspirates of children with respiratory tract infection (13, 14). MCPyV was 
in 2008 found in a rare but aggressive skin tumor  MCC (6). HPyV6 and HPyV7 were in 
2010 identified in the skin swabs from healthy persons (15), and TSPyV in the lesion of a 
rare skin disease  TS (9). HPyV9, phylogenetically close to the B lymphotropic 
polyomavirus (LPyV) of African green monkey, was in 2011 detected in the blood and 
urine of asymptomatic kidney transplant recipients (16). Subsequently, the following three 
were discovered sequentially: HPyV10/MWPyV/MXPyV in stool samples of children 
with diarrhea and anal condylomas (17-19), STL polyomavirus (STLPyV) in feces of 
diarrheal as well as healthy children (20), and HPyV12 in organs of the digestive tract (21). 
1.1 Classification and virion properties 
In the past, polyomaviruses were classified as members of the genus Polyomavirus in the 
family Papovaviridae, which included papillomaviruses, polyomaviruses, and the simian 
vacuolating agent 40 (SV40). In 2000, polyomaviruses were separated into an independent 
family, Polyomaviridae, which contained a sole genus including different species. Since 
2011, by the criteria of host range and genetic relationship, polyomaviruses have been 
grouped into three genera: two mammalian virus genera named Orthopolyomavirus and 
Wukipolyomavirus, and an avian virus genus named Avipolyomavirus (22, 23). The genus 
Wukipolyomavirus comprises viruses infecting humans: WUPyV, KIPyV, HPyV6 and 
HPyV7, among which KI polyomavirus is the type species (22). The genus 
Orthopolyomavirus, with Simian virus 40 serving as type species, contains human 
(BKPyV, JCPyV, MCPyV and TSPyV) and other mammalian polyomaviruses (22, 23). 
Polyomavirus particles are non-enveloped and composed of icosahedral capsids of 40-
45nm in diameter. The capsids contain 72 capsomers in a skewed lattice arrangement and 
one pentameric capsomer consists of five VP1 molecules associated with one molecule of  
either VP2 or VP3 (24, 25). The VP1, the major capsid protein, constitutes over 70% of 
the total content of virus particles. The VP2 and VP3 are thought to help with virus entry, 
and to function in the encapsidation of viral genomes in the formation of virions (22, 23). 
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The nonenveloped virions have a buoyant density of 1.34-1.35g/cm
3
 in CsCl gradients, 
and are resistant to ether, acid and heat treatment (1, 23, 25, 26). 
Names 
Year of 
Discovery 
Associated diseases Source of isolation References 
JCPyV or JCV 1971 PML Brain 11 
BKPyV or BKV 1971 
PVAN, 
 haemorrhagic cystitis 
Urine 12 
KIPyV 2007 None 
Nasopharyngeal 
tissue 
13 
WUPyV 2007 None 
Nasopharyngeal  
tissue 
14 
MCPyV or MCV 2008 MCC MCC lesion 6 
HPyV6 2010 None Skin 15 
HPyV7 2010 None Skin 15 
TSPyV or TSV 2010 TS TS lesion 9 
HPyV9 2011 None Blood, urine, skin 16 
HPyV10/MWPyV/
MXPyV 
2012 None Stool, wart 17,18,19 
STLPyV 2012 None Stool 20 
HPyV12 2013 None Liver 21 
Table 1. Human Polyomaviruses. Modified by permission from DeCaprio et al. 2013 (27). 
1.2 General aspects of HPyV life cycle  
Polyomaviruses can infect their natural hosts to commence a productive life cycle that 
results in nuclear DNA replication, assembly of the viral capsid, and release of virions by 
cell lysis (1). HPyVs attach to the host cell by the interaction of VP1 with receptors on the 
host cell membrane, and after attachment, enter the cell by endocytosis through various 
pathways (1). For example, JCPyV attaches to the cell through sialic acid and 5HT2A 
serotonin receptor, and enter the cell through the clathrin-mediated pathway, whereas 
BKPyV interact with sialic acid of gangliosides on the cell membrane and depends on the 
caveolin-mediated pathway to enter the cell (28-32). Recently, MCPyV VP1 has been 
shown to bind to heparan sulfate of glycosaminoglycans and sialic acids on ganglioside 
GT1b sequentially for infectious entry (33, 34). After entry, polyomaviruses are 
transported through the cytosol to the nucleus, where the early transcription occurs (1, 35). 
The early-gene product T antigen initiates replication of viral genome and transcription of 
late genes. After translation, the late-gene products VP1, VP2 and VP3 are translocated 
into the nucleus, and assemble with viral genomes into virions. The virions are finally 
released from the cell probably by cell lysis (1, 36-38).  
Polyomaviruses can establish in non-permissive cells a non-productive infection that 
results in viral early gene expression in absence of viral genome replication. The 
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interaction between viral T antigens and tumor suppressor proteins will lead to abnormal 
cell cycle progression, the result of which is oncogenic transformation (39). In permissive 
cells, cellular transformation by T antigens rarely occurs because the release of virions 
leads to cell death. However, in non-permissive cells, T antigen expression can induce 
oncogenic transformation (36). On the other hand, if viruses undergo mutations resulting 
in their disability to complete lytic replication, oncogenesis may occur (1). Among HPyVs, 
BKPyV and JCPyV are integrated into the chromosomal DNA by recombination, and 
develop tumors in their non-natural hosts (2, 3, 36). MCPyV in MCC presents the first 
evidence that an HPyV is integrated into the natural host genome and associated with a 
cancer (6). 
1.3 General aspects of HPyV infection and diseases 
HPyVs, as a rule, establish persistence or latency in humans after primary infection, and in 
some rare cases, they reactivate and lead to pathological processes (37, 40, 41). It is a 
common feature among HPyVs that infections with these viruses are ubiquitous in the 
general population (37). After a short period of viremia following the first exposure, the 
viruses are thought to escape elimination by the host’s immune mechanisms and establish 
a lifelong persistent infection in the human body (37). The sites of persistence are not 
clearly known, but HPyV DNA is shown in a number of human organs. JCPyV and 
BKPyV DNA are detected in tonsils, urogenital system, colon, lymph nodes, bone marrow, 
blood cells and the central nervous system (42). Among asymptomatic individuals, low-
level secretion of BKPyV and JCPyV occurs in the urinary tract, suggesting that the viral 
genome persisting in kidney and urogenital system intermittently replicates (42-45).  
HPyVs can reactivate from latency, actively replicate and cause disease. During this, 
virions can be visualized and viral capsid proteins detected in affected tissues (37). 
Different from the asymptomatic low-level virus replication described above, the viral 
genome synthesis under reactivation is usually at a high level and associated with the 
formation of virions. Under immunosuppression, JCPyV can reactivate in the human brain 
and cause PML  a disease associated with HIV/AIDS and as side effect of 
immunomodulatory therapies (40, 46, 47). In the case of PML, active replication of 
JCPyV in oligodendrocytes destroys myelin-producing cells, resulting in brain lesions and 
death (47). Similarly, BKPyV can reactivate from latency in immunocompromized 
individuals, and cause nephropathy. In renal transplant recipients, BKPyV replication in 
their kidney cells causes polyomavirus-associated nephropathy (PVAN)  a leading cause 
of allograft failure associated with immunosuppressive therapies (48-50). In addition, 
BKPyV replication in the urothelium causes hemorrhagic cystitis (51). Notably, JCPyV 
replication is observed in the brain of almost all of PML patients, and BKPyV replication 
is found in kidneys of 80% of renal transplant patients with 10% progressing to PVAN (52, 
53). Moreover, the viremia of JCPyV and BKPyV rarely occurs in healthy individuals 
after primary infection, but appears in 17% of PML patients and up to 100% of PVAN 
patients, suggesting that an active viral replication bypassing the control of host immunity 
is associated with the progression of these diseases (40, 48, 54, 55).  
  
 
 
13 
To date, among the recently found HPyVs, KIPyV and WUPyV are predominantly 
found in nasopharyngeal aspirates, bronchoalveolar lavages, and feces from pediatric 
patients (56-58). Though initially found in nasopharyngeal aspirates from children with 
respiratory infections, these two viruses have been later shown to lack a clear etiological 
link to respiratory disease (13, 14, 58, 59). The shedding of KIPyV and WUPyV, similar 
to that of JCPyV and BKPyV, increases with immunosuppression (60, 61). MCPyV, 
considered to participate in the development of MCC, has been detected in approximately 
75% MCC tumors with clonal integration, whereas the virus is also present in the healthy 
skin, and other tissues (7). HPyV6 and 7, predominantly present in cutaneous swabs from 
healthy persons, have not been reported to be associated with any diseases (15, 62). 
TSPyV is mostly present in the inner-root sheath cells of hair follicles in TS lesions, and 
thought to play a role in the pathogenesis of TS disease (9, 10). HPyV 9 is occasionally 
observed in plasma, urine and skin swabs (16, 63, 64), but no linkage to any disease has 
been established so far. There are few reports on HPyV10, STLPyV, and HPyV12, of 
which the first two have been occasionally seen in stools and the latter might be related to 
the digestive tract (17-21). Their disease association remains unclear. 
2. Merkel cell polyomavirus 
2.1 Merkel cell carcinoma 
MCC is a highly aggressive skin cancer of neuroendocrine origin, with high rates of 
recurrence and metastasis (65). The tumor, named after its possible cell of origin, is 
thought to arise from mechanoreceptor Merkel cells in the basal layer of the epidermis 
(66). Some studies argued for a stem cell as the tumor origin, since some MCCs showed 
epithelial and sarcomatous features (67). The controversy seems to be explained by a 
recent finding that demonstrates mammalian Merkel cells developing from epidermal stem 
cells (68).   
MCC has incidence rates of 0.18-0.41 per 100 000 persons, occurs predominantly 
among Caucasians between 60 and 85 years of age, and the incidence rate is about twice 
as high in males than in females (67). Because of the improvement of diagnostic 
techniques, the age-adjusted incidence rate seems to have tripled during the past 20 years 
(69). The overall 5-year relative survival rate is about 60% (65), and among patients with 
local, nodal, and metastatic disease, the rates are 64%, 39% and 18%, respectively (70). 
The tumor arises predominantly in the skin of head and neck, but can also occur at 
extracutaneous sites including salivary glands, nasal cavity, lip, lymph nodes, vulva, 
vagina and esophagus (67). The clinical features of MCC are summarized as AEIOU: 
asymptomatic/lack of tenderness, expanding rapidly, immune suppression, older than 50 
years, and ultraviolet exposed site on a person with fair skin (71).  
MCC has been observed most often in sun-exposed skin of Caucasians, pointing to 
ultraviolet exposure as a major risk factor for tumorigenesis (69, 71). In a study of 1380 
psoriasis patients treated by ultraviolet phototherapy, three developed MCCs, an incidence 
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rate 100 times higher than expected in the general population (72). Another significant risk 
factor is immunosuppression. MCC occurs more frequently in severely 
immunosuppressed populations, such as patients with HIV/AIDS and leukemia, and after 
organ transplantation (73-77). Patients with AIDS have a 13-fold increased risk for MCC, 
compared with the general population (75). The MCC incidence is also associated with the 
occurrence of other cancers, such as squamous cell carcinomas, basal cell carcinomas and 
malignant melanoma, suggesting the existence of shared risk factors among these cancers 
(78). 
2.2 Discovery of MCPyV 
Using the digital transcriptome subtraction technique, Feng et al. in 2008 discovered a 
previously unknown human polyomavirus in MCC (6). This approach combines high-
throughput cDNA sequencing and in silico methods to sequentially exclude human 
sequences from a diseased tissue sample transcriptome (79). In the case of MCPyV, 
cDNA libraries were generated with random RT-PCR from MCC tumors and sequenced. 
Known human sequences were subtracted from MCC cDNA libraries by the help of 
specific software, and some transcripts were detected with similarity to LPyV and BKPyV. 
By viral genome walking, two complete MCPyV genomes MCPyV350 and MCPyV339 
were obtained. Meanwhile, MCPyV DNA was observed in eight of ten MCCs, and in six 
of them the viral genome was integrated into the tumor genome (6). Importantly, the 
patterns of integration suggest that MCPyV infection and integration occur preceding the 
clonal expansion of the tumor cells. 
2.3 MCPyV genome structure and function 
MCPyV has similar genome structures to those found in other polyomaviruses. The 
genome of MCPyV is approximately 5.4kb in length, and composed of three functional 
parts: the early and late regions with a non-coding control region (NCCR) in between 
(Figure 1). The early region encodes non-structural proteins (tumor antigens), which are 
involved in viral DNA replication and gene expression. The late region encodes structural 
proteins, which assemble into viral particles. The NCCR contains a single origin of DNA 
replication and the transcriptional control elements. The early and late regions, without 
overlapping in their sequences, bidirectionally generate transcripts from the opposite 
strands of DNA (1, 22, 80). The early antigens large T antigen (LT), small T antigen (sT) 
and 57kT antigen are generated from a common pre-mRNA via alternative splicing, and 
thus share identical N-terminus but possess different C-terminal DNA sequences (8). The 
agnoprotein, which exists in JCPyV and BKPyV, has not been seen in MCPyV or in any 
other novel HPyVs (22, 81) 
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Figure 1 The genome organization of MCPyV. Reproduced by permission from Feng et al. 
2008 (6). 
The large T antigen 
MCPyV LT retains conserved domains that are essential for replication of viral genome 
and regulation of viral gene expression. These domains include the origin-binding domain, 
helicase/ATPase domain, retinoblastoma protein (pRb) binding domain, and the DnaJ 
domain (7, 8, 82-84). LT plays an important role in initiation of viral replication. In the 
case of SV40, LT binds to GAGGC motifs at the viral origin and recruits cellular 
replication proteins to initiate viral replication (85-89). The ATPase activity of LT 
enhances the assembly of the LT-origin complex, and helicase activity helps unwind the 
double-stranded DNA (88, 90). With MCPyV, a similar function of LT has been 
demonstrated for viral replication. MCPyV harbors GAGGC-like pentanucleotides that 
serve as LT binding sites (6, 8, 82, 91). Importantly, MCPyV tumor-derived LT, without 
the origin-binding domain or helicase domain, reduces LT-origin assembly and fails to 
initiate MCPyV origin replication (8, 82).      
The DnaJ domain, located at the very N-terminus of LT, acts as a co-chaperone 
regulator, binding chaperone Hsc70 and stimulating its ATPase activity. The DnaJ-Hsc70 
chaperone is able to mediate rearrangements of the initiation complex leading to the 
stimulation of viral DNA replication (92-95). An intact DnaJ region has been shown to be 
compulsory for MCPyV replication (82).  
The pRb family proteins form a complex with E2F transcriptional factors to repress 
genes that are associated with cell cycle progression, DNA replication, DNA repair, 
differentiation, and apoptosis (96, 97). The release of pRb from E2F can be induced by 
DnaJ domain-mediated hydrolysis of Hsc70 ATP, and the LT intrinsic pRb-binding 
LXCXE motif. The release of pRb from E2F leads to transactivation of E2F-responsive 
genes and thus promotes cell proliferation (88, 92, 98). Both the pRb-binding LXCXE 
motif and DnaJ domain are conserved in MCPyV LT (8, 84). An intact pRb-binding motif 
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is required for promoting the proliferation of MCC cells (99). Consequently, the targeting 
of LT with pRb induce survivin expression, which is critical for the survival of MCPyV-
positive MCC cells (100).  
The tumor suppressor protein p53 binding domain, which has been found in the LT of 
SV40, BKPyV and JCPyV (80), is absent from MCPyV LT (8, 101). p53 is responsible 
for repressing abnormal cellular proliferation, stimulating apoptosis and regulating DNA 
repair (102, 103). The binding of LT to p53 leads to abnormal cell proliferation (104). The 
lack of a p53-binding site in MCPyV LT suggests factors other than p53 inactivation 
involved in MCPyV tumorigenesis. Bub1 is a mitotic spindle checkpoint protein kinase 
responsible for correct chromosome segregation (105, 106). Neither is the Bub1 binding 
site, another LT targeting motif conserved in most polyomaviruses, found in MCPyV (80).  
MCPyV LT contains a nuclear localization signal (107), and the nuclear localization of 
LT is observed in cell cultures as well as in the MCC tumors (108). In addition, MCPyV 
contains a unique region in the T antigen, which is called the “MCPyV-Unique Region”. 
This unique region interacts with the cytoplasmic protein Vamp6 and redistributes it to the 
nucleus, preventing Vamp6 function in lysosome clustering (83).  
The small T antigen 
MCPyV sT shares with LT approximately 80 N-terminal amino acids and possesses a 
unique C-terminus (8). Compared to LT, larger quantities of sT are detectable in MCC 
tumors (109). With SV40, LT is a potent in vitro transforming oncoprotein, whereas with 
MCPyV, sT functions in the cellular transformation (82, 109). MCPyV sT expression is 
essential for cell transformation but not compulsory for tumor cell growth and survival 
(109, 110). The sT induces transformation not through interacting with phosphatase 2A, 
but rather by promoting hyperphosphorylation of 4E-BP1 (109). The 4E-BP1 is a 
downstream target of the mTOR signaling pathway, which is critical for tumor cell 
survival in many types of genetic cancers (111).  
57kT 
The MCPyV early transcript encodes an additional protein of Mr57000, named 57kT. This 
protein, identical to LT except for a deletion in the C-terminal region, contains a pRb-
binding site but eliminates the origin-binding domain and the DNA helicase/ATPase 
domain (6, 83). The biological function of 57kT is unclear, but the protein is thought to be 
an analog of the SV40 17 kT antigen, which appears to function in the process of cellular 
proliferation (112, 113). 
Capsid proteins 
The late region of HPyV genome, such as SV40, encodes structural proteins required for 
viral assembly, including a major capsid protein VP1 and two minor proteins VP2 and 
VP3. These proteins are generated from alternatively spliced mRNAs. The latter two are 
overlapping, with the entire VP3 sequence located at the C-terminus of VP2. The 
translation of VP3 initiates at a highly conserved motif within VP2 open reading frame (6, 
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114). However, phylogenetic analysis has shown that MCPyV lacks the conserved VP3 N-
terminal motif, indicating the absence of a functional VP3 protein in this virus (115, 116). 
Correspondingly, in MCPyV-infected cells, VP3 is neither detectable in cell lysate nor 
present in MCPyV native virions (116). It has been demonstrated with SV40 that the viral 
VP2 and VP3 are transported into the nucleus depending on VP1, and probably act in 
trafficking of incoming virus to the nucleus in the early phase of infection (98, 117, 118). 
In the case of MCPyV, the viral VP2 is shown to be compulsory for efficient MCPyV 
infectious entry into certain cell types (116). 
MicroRNA 
Viral-encoded microRNA has been detected for MCPyV (119, 120). A microRNA 
MCPyV-miR-M1-5p is expressed at low levels in 50% of MCPyV-positive MCCs (119). 
MCPyV microRNA is antisense to early transcripts and can negatively regulate LT 
expression late in infection (119). This downregulation of LT levels may be involved in 
immune evasion of the virus, compared to the function of SV40 microRNA (121). 
2.4 Infection and immunity 
MCPyV infection is ubiquitous in the general population, as MCPyV specific antibodies 
are detected in a large proportion of healthy persons. The seroprevalence of MCPyV is 60-
80% among adults (122-126). In contrast to the normal population in MCC patients with 
MCPyV-positive tumors the seroprevalence of MCPyV is up to 100% and these patients 
also have higher antibody titers than healthy individuals (115, 126-128). One possible 
explanation is that the immunosuppressed status of MCC patients allows reactivation of 
MCPyV, leading to a stage of viremia preceding tumor development. The other is that 
MCC patients have been challenged with a high virus burden to stimulate antibody 
responses. It has been shown that the antibody levels correlate with the presence of viral 
DNA in the skin irrespective of disease, and that MCC patients have high MCPyV viral 
load in their unaffected skin (129, 130). However, VP1 antibody levels are not associated 
with tumor viral loads, but are associated with a better progression-free survival in MCC 
patients (128). In a subset of MCC patients, antibodies against LT are detected (131). The 
levels of LT antibodies correlate strongly with the presence of MCPyV DNA and the 
expression of T antigens in MCC tumor cells (131). Interestingly, elevated LT antibody 
levels are associated with progression of the disease, suggesting that LT antibody cannot 
protect MCC patients against cancer progression, but may serve as a clinically useful 
indicator of disease status (131). 
With MCPyV, cellular immunity apparently plays an important role in the control of 
the virus and of MCC formation. Tumor infiltrating lymphocytes are present in MCPyV-
positive tumors (132-134), and high counts of intratumoral T cells contribute to favorable 
survival in MCC patients (132, 133). When implanted into immunodeficient mice, MCC 
tumors fail to grow unless T cells in the tumor grafts are depleted, suggesting that tumor-
specific T cells are essential in controlling tumor growth (135). Circulating T cells and 
tumor-infiltrating T cells can recognize specific peptides from MCPyV LT antigen and 
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capsid protein, and circulating T-cell responses are detectable regardless of MCC (134). 
MCPyV-specific T-cells against VLPs are found in blood from healthy persons. 
Compared to MCPyV-seronegative individuals, MCPyV-seropositive subjects show 
significantly stronger IFN-γ responses, suggesting that T-cells play a critical role in the 
control of MCPyV in the general population (136). Obviously, as host immune functions 
are important in the progression of MCC, boosting host immune response might be a 
novel therapeutic or prophylactic option for this cancer.  
2.5 Molecular epidemiology  
MCPyV, since its discovery, has been shown in MCCs worldwide. Overall, MCPyV is 
detectable in 75% of MCCs (7), with integration into human genome and tumor-specific 
mutations (6, 137-140). Using a more sensitive detection method, a recent study implies 
that the rate of MCPyV detected in MCC must be higher than those reported (141). 
MCPyV is found in MCC tumors irrespective of the sites of origin (142), and as shown 
with MCC patients in their unaffected skin, nasal swabs, urine samples, and peripheral 
blood mononuclear cells (PBMCs) (137, 139). Among these latter samples, only PBMCs 
have been shown with integrated forms of MCPyV, probably due to circulation of 
metastatic cells (139). Nevertheless, in MCC patients, compared to non-MCC tissues, 
MCC tumors generally show higher MCPyV prevalence and higher viral load (137, 143-
145). 
MCPyV is shed predominantly in the epidermis of normal skin (15, 130, 137, 143, 
145). In one study, MCPyV DNA was found in cutaneous swabs of all participants (130). 
In another study, MCPyV genomes of wild type (without mutation and integration) were 
recovered from 40% of skin swabs of healthy adults (15). The viral load does not differ in 
the skin biopsy samples from MCC and non-MCC individuals (137), but are of higher 
level in cutaneous swabs than in skin biopsies from MCC patients (130). Besides in skin, 
MCPyV has been detected in various tissues, including respiratory tract and its secretions 
(146-148), tonsillar biopsies (148), lung tissues (143, 144, 149), oral mucosa (150), saliva 
(130, 143), anogenital samples (143, 145), digestive tract (143, 151), lymphoid tissue (61, 
152), urine (153, 154) and blood (144, 148, 154-156) (Table 2). The level of MCPyV 
DNA is higher in the digestive system than in the respiratory and genitourinary systems 
(143). HIV patients have MCPyV detected in normal tissues more frequently than healthy 
persons have (157, 158). However, renal transplant patients show MCPyV shedding in 
urine at low level regardless of immunosuppression (159). Notably, viral mutation and 
integration have not been reported so far in any type of non-tumor tissues of individuals 
without MCC.  
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Study Sample materials 
MCPyV 
DNA 
Schowalter et al. (15) Forehead skin swabs of 35 volunteers 40% 
Foulongne et al. (130) Cutaneous swabs of 25 healthy volunteers 100% 
Loyo et al. (143) 21 non-MCC skin samples 48% 
Wieland et al.(145) 34 healthly skins from immunocompetent patients 24% 
Wieland et al. (145) 14 plucked eyebrow hairs from 14 HIV+ patients 50% 
Bialasiewicz et al. (146) 
526 respiratory tract samples from patients with 
upper or lower respiratory tract symptoms 
1.3% 
Goh et al. (147) 635 nasopharyngeal aspirate samples 4.2% 
Kantola et al. (148) 
140 nasopharyngeal aspirate samples from 
wheezing children 
2.1% 
Kantola et al. (148) 229 tonsillar tissues from asymptomatic children 3.5% 
Loyo et al. (143) 43 samples of lung 26% 
Fukumoto et al. (144) 17 pneumonia samples 18% 
Bergallo et al. (149) 
66 transbronchial biopsies from lung transplant reci
pients 
33.8% 
Foulongne et al. (130) buccal mucosa swabs of 42 pateints 4.8% 
Wielande et al. (145) 
120 mucosal samples (anal, penile, oral) from HIV+ 
men 
31% 
Loyo et al. (143) 10 saliva from patients without cancer 100% 
Loyo et al. (143) 10 samples of bladder 60% 
Wielande et al. (145) 
27 anogenital samples from an immunodeficient 
patient 
74% 
Loyo et al. (143) 37 samples of liver tissue  54% 
Loyo et al. (143) 50 samples of colon tissue 18% 
Pancaldi et al. (155) 60 buffy coats of healthy blood donors 22% 
Kantola et al. (148) 
840 sera from immunocompromised and 
immunocompetent individuals 
0.1% 
Fukumoto et al. (144) 23 serum samples from HIV patients 39% 
Sadeghi et al. (156) 
621 serum samples from 394 hospitalized elderly 
individuals 
10% 
Shuda et al. (108) 21 PBMC from HIV+ patients 14% 
Toracchio et al. (152) 
29 normal lymph nodes from patients with 
metastatic carcinoma or melanoma 
10.3% 
Sharp et al. (61) 
55 lymphoid tissue samples (lymph node and 
spleen) from immunocompetent individuals 
1.8% 
Table 2. MCPyV DNA prevalence among non-tumor samples. 
MCPyV has been detected in a number of tumor types other than MCC, particularly in 
skin cancers. MCPyV is detectable in 15-35% of squamous cell carcinomas, which is the 
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second most frequently diagnosed skin cancer and associated with immunosuppression 
(150, 160-168). In one study, MCPyV has been identified in 52% of squamous cell 
carcinomas from immunocompromised and in 25% of squamous cell carcinomas from 
immunocompetent individuals (160). MCPyV is also present in  basal cell carcinomas 
(162, 165), adenocarcinomas (163, 164), large-cell carcinomas (163), pleomorphic 
carcinomas (163), lymphomas (152, 169-171), colon cancers (151), non-small cell lung 
carcinomas (172), and Kaposi's sarcomas (173). Viral DNA integration and mutation were 
reported in a few cases, such as squamous cell carcinomas and adenocarcinomas (163), 
but the detection rates seem incidental. However, in one study, six of 19 MCPyV-positive 
chronic lymphocytic leukemia cases showed a truncating MCPyV large T antigen deletion, 
suggesting a potential role of MCPyV in a subset of chronic lymphocytic leukemias (174). 
2.6 Clinical aspects on MCPyV-positive and -negative MCCs   
A majority of MCCs (approximately 75%) have MCPyV involved in their pathogenesis, 
whereas those tumors negative for the virus, must stem from other etiological pathways. 
Accordingly, a number of MCC research groups have investigated the clinical differences 
between the tumors with and without MCPyV. Compared to virus-negative tumors, as a 
general conclusion, MCPyV-positive MCCs are more frequently present on the 
extremities such as limbs, and less often on the trunk (175-177). Several studies have 
demonstrated that MCPyV-positive tumors are less frequently present in patients with 
metastases at diagnosis (139, 175, 176), though this conclusion was not reached in a 
subsequent study (177). In a small-size study of 26 MCC cases, a Japanese group 
observed more irregular nuclei and more abundant cytoplasm in virus-negative than in 
virus-positive tumors (178). Recently, this research group further proved this observation 
with additional 43 MCC samples (179). However, with 144 MCC cases originating from 
Australia and Germany, Schrama et al. did not observe significant differences between 
MCPyV-positive and -negative tumors concerning histological type, microanatomic 
compartment, mitotic rate and expression of p16, p53, RB1, and Ki67 (177). 
The reports on the effect of MCPyV status on MCC outcome seem contradictory. 
Some investigators found patients with MCPyV-positive tumors associated with better 
survival than those with MCPyV-negative ones (175, 176, 180, 181), whereas others did 
not observe such association (168, 177, 182). This discrepancy might be due to different 
composition of study materials, as MCPyV-positive MCCs are likely composed of two 
subgroups of tumors with distinct clinical features. Together with MCPyV-negative 
tumors, MCCs can be divided into three distinct groups based on the MCPyV status, viral 
load and T-antigen expression, i.e. MCC with high, low and no viral detection (168, 175, 
180, 183, 184). MCC tumors with high MCPyV detection show correlations between viral 
load, pRb expression, LT expression, absence of p53 expression, and better clinical 
outcome (180, 183, 184). However, MCC tumors with low or no MCPyV detection are 
predominant in p53 expression but lack LT and pRb expression, suggesting a different 
route involved in the MCC development (180, 184, 185). 
Tuoze et al. postulated that tumors without or with MCPyV at a low viral burden, 
developing from a similar etiology, compose a group of MCCs with a progressive 
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phenotype, while MCCs with a high MCPyV burden, presence of LT expression, and high 
level of MCPyV antibodies, compose the other group with a less aggressive phenotype 
(128). Recently, a study identified a new type of MCPyV-positive MCC, in which the cell 
growth is T-antigen independent. This finding, too, supports that alternative pathways 
other than the T antigen-based may be associated in the formation of certain MCPyV-
positive MCC tumors (186). Moreover, this study suggests that some MCC tumors may 
only need MCPyV for tumor initiation and lose the virus during tumor progression, 
comprising the MCPyV-negative MCCs with a progressive phenotype (186). 
2.7 Association of MCPyV with pathogenesis of MCC 
The criteria proposed by zur Hausen for defining a causal role for an infection in cancer 
are (187): "(i) Epidemiological plausibility and evidence that a virus infection represents a 
risk factor for the development of a specific tumor. (ii) Regular presence and persistence 
of the nucleic acid of the respective agent in cells of the specific tumor. (iii) Stimulation of 
cell proliferation upon transfection of the respective genome or parts therefrom in 
corresponding tissue culture cells. (iv) Demonstration that the induction of proliferation 
and the malignant phenotype of specific tumor cells depend on functions exerted by the 
persisting nucleic acid of the respective agent." 
A number of evidences support an association between MCPyV and the pathogenesis 
of MCC. (i) MCPyV has been detected in a large proportion of MCCs regardless of the 
geographical distribution, and the tumor-associated viral genome is integrated into the 
host cells by a monoclonal pattern (6, 139, 140). (ii) The metastatic tumors reveal the 
same monoclonal pattern of integration as the primary tumor, suggesting that viral 
integration is an early event in tumorigenesis preceding tumor cell expansion and tumor 
progression (6). (iii) The integrated MCPyV harbors specific mutations in the LT gene 
resulting in truncated LT expression, while MCPyV genomes found in non-MCC tissues 
are wild-type (6, 139, 154, 188). (iv) MCPyV LT contains motifs critical for virus-positive 
tumor cell replication and survival in the case of viral integration (8, 99, 108, 110, 184, 
189, 190). (v) MCPyV sT functions in cell transformation (109). However, 
epidemiological investigations show that MCPyV presents as a constituent of normal skin 
flora and infection with this virus is widespread in the general population.  
To answer how this ubiquitous viral infection eventually causes a rare skin cancer, 
virologists have proposed a model, wherein a series of rare mutagenic events associated 
with loss of immune control are involved in MCC formation (7, 191, 192). As shown in 
Figure 2 (191), MCPyV infection occurs asymptomatically in the early childhood (126, 
193, 194). UV radiation or other environmental factors may induce integration of MCPyV 
into the host cell genome (6). If the wild-type MCPyV T antigen induces DNA to replicate 
from the origin of replication of the integrated virus, the host-cell DNA strands break, 
which would lead to cell death. On the other hand, if a second mutation is induced to 
generate a truncated T antigen without replication capacity but with oncogenicity (195), 
the nascent tumor cell survives (8). The persistent expression of T antigen drives the 
pathogenesis of MCC (99, 109, 189). In addition, loss of immune control through ageing, 
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AIDS or immunosuppressive therapy, allows for an increase of MCPyV burden in the skin 
as well as T-antigen expression (115, 126, 129, 131). 
 
Figure 2 The molecular evolution of MCPyV in the pathogenesis of MCC. Reproduced with 
permission from Moore & Chang 2010 (191). 
Notably, T antigen as oncoprotein plays a key role in MCC pathogenesis. MCPyV LT 
expressed in MCC tumors is uniformly truncated, retaining the pRb binding or LXCXE 
motif but eliminating the DNA binding and helicase domains (6, 8, 192, 196). In MCC 
cell lines and xeno-transplantation models, knockdown of this viral LT leads to growth 
inhibition while restoration of LT expression leads to rescued cell growth, indicating that 
LT expression is a critical factor in the formation of MCPyV-positive MCC tumors (99, 
189). Moreover, an intact pRb-binding site is required for LT to rescue cell growth (99). In 
a recent study, expression of LT C-terminal 100 residues showed inhibitory activities in 
growth of several cell types, suggesting that the deletion of the C terminus of LT may also 
result in the loss of a growth-inhibitory function intrinsic to this region (101). The sT is 
UV-inducible, and capable of transforming human cells by targeting 4E-BP1 (109). 
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3. Trichodysplasia-spinulosa associated polyomavirus 
3.1 Trichodysplasia-spinulosa disease 
TS is a rare skin disease only observed in severely immunocompromised patients, such as 
solid organ transplant recipients and patients with leukemia and lymphoma (10, 197, 198). 
The disease is characterized by the appearance of follicular-based papules and keratin 
spikes on the skin, sometimes along with alopecia of the eyebrows and eyelashes (197, 
199). The lesions appear most often in the face, especially the nose, eyebrows and auricles, 
but also in other parts of the body (200). The histological features include abnormal hair 
follicle maturation with the follicles distended and enlarged, and high production of inner 
root sheath cells with excessive amounts of trichohyalin (9, 197, 199). In 1999, Haycox 
and co-workers first introduced the term "trichodysplasia spinulosa" to describe this skin 
disorder in a renal/pancreas transplant patient with immunosuppressive regimen (199). 
They also proposed a viral origin for TS, because by electron microscopy (EM) 
honeycomb-arranged viral particles with papovavirus morphology were seen in the 
affected follicle clusters (199). Subsequent reports confirmed the presence of 
polyomavirus-like particles, and the entity was termed "virus-associated trichodysplasia 
spinulosa" (201-206).  
3.2 Discovery of TSPyV 
In 2010, using rolling-circle amplification (RCA), van der Meijden et al. identified in TS 
lesions a previously unknown human polyomavirus  designated TSPyV or TSV (9). The 
technique employed the DNA polymerase of bacteriophage phi29, an enzyme with strand 
displacement and proofreading activities. With random primers, the polymerase can 
efficiently amplify circular DNA molecules from complex biological samples (207). For 
TSPyV identification, the DNA extracts of the TS lesions were subjected to RCA, 
followed by restriction enzyme digestion. Based on the sizes of digestion products, the 
amplicon was estimated to be about 5000 bp in length, a size typical for the genome of 
known polyomaviruses. Through sequencing of the RCA fragments, the entire TSPyV 
genome was obtained (9). With a close phylogenetic relation to Bornean orangutan 
polyomavirus, TSPyV is categorized into the genus Orthopolyomavirus (9, 22, 23). 
3.3 TSPyV genome 
TSPyV has a double stranded DNA genome of 5232 base pairs (Figure 3) (208). Based on 
an analysis of the putative viral sequence, the components commonly found in 
polyomaviruses have also been revealed in the TSPyV genome  two early genes (LT and 
sT) and three late genes (VP1, VP2 and VP3) with NCCR in between. The early and late 
genes reside on the opposite strands, with an organization similar to that of other 
polyomaviruses. The putative LT-binding sites, origin and TATA box are present in 
NCCR. The LT sequence is characteristic, including DnaJ-domain, pRb-binding motif, the 
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origin-binding domain, ATPase/helicase domain, and a nuclear localization signal. The 
putative TSPyV sT contains PP2A-binding motifs (9). The potential functions of these 
motifs and domains are similar to those described for MCPyV. 
 
Figure 3 The genome organization of TSPyV. Reproduced with permission from Kazem et al. 
2013 (208). 
3.4 Epidemiology and immunity 
The presence of TSPyV in TS disease has been confirmed by a number of case reports 
after the discovery of TSPyV. Extracted from TS lesions, the TSPyV sequences were 
amplified by PCR, and viral particles observed by EM (197, 209). Notably, by analyzing 
all available TS cases worldwide, Kazem et al. showed the relation of TSPyV infection 
with TS disease (10). In their study, TSPyV DNA was detectable in the lesional samples 
of all TS cases, whereas only in 2% of forehead skin swabs from healthy controls (10). 
The viral load in the TS lesions is 1,000,000-fold higher than that in the forehead skin of 
TS patients, and 10,000 – 100,000-fold higher than that in asymptomatic controls, 
suggesting that a high rate of TSPyV replication occurs in TS-affected skin (10). 
Moreover, TSPyV VP1 was present in all lesional TS samples, and restricted to the nuclei 
of the inner root sheath cells that over-expressed trichohyalin. However, the VP1 was 
absent from the non-lesional samples (10), indicating that an active TSPyV infection is 
involved in the development of TS. Furthermore, in several studies, TS patients  ´
conditions improved, when treated with anti-viral drugs, for instance cidofovir, which can 
selectively inhibit viral DNA polymerase and thus suppress viral replication (9, 201) . 
So far, TSPyV has been searched in various non-TS samples including skin swabs, 
plucked eyebrows, nasopharyngeal swabs, feces, urine, blood, and cerebrospinal fluid 
(208). However, the viral DNA is only present in less than 5% of the samples from 
asymptomatic individuals, regardless of whether they are immunosuppressed or 
immunocompetent (208). TSPyV DNA has been shown in 4% of plucked eyebrows, 2% 
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forehead skin swabs, 3% nasopharyngeal swabs, 3% fecal and 1% urine samples (Table 3) 
(9, 10, 16, 208, 210). Viral DNA has, however, not been detected in blood and 
cerebrospinal fluid (16, 156, 208). In the case report by Fischer et al., TSPyV DNA was 
found in a renal allograft biopsy specimen of a TS patient (211). In two independent 
studies investigating TSPyV in cancers, TSPyV DNA was absent from various skin 
cancers such as pilomatricomas, basal cell carcinomas and squamous cell carcinomas (165, 
212). In contrast, a seroepidemiological study showed TSPyV infection to be ubiquitous in 
the general population (208). In addition, T-cell immunity against TSPyV has been 
studied in healthy persons. Interestingly, using a VP1-VLP antigen, the TSPyV T-cell 
responses did not differ between virus-seropositive and seronegative subjects (213). 
Study Sample materials 
TSPyV 
DNA 
van der Meijden et al. 
(9) 
Plucked eyebrows from 69 immunosuppressed 
renal transplant patients 
4% 
Kazem et al. (208) 
Plucked eyebrows from 81 renal transplant 
patients 
2% 
Kazem et al. (10) Forehead skin swabs of 249 healthy individuals 2% 
Siebrasse et al. (210) Nasopharyngeal swab from 32 transplant patients 3% 
Siebrasse et al. (210) Fecal samples from 32 transplant patients 3% 
Kazem et al.(208) 
160 fecal samples from pediatric patients with 
gastroenteritis 
1% 
Scuda et al. (16) 
38 fecal samples from pediatric patients with 
gastroenteritis 
0% 
Scuda et al. (16) 
179 urine samples from immunocompromised 
patients  
1% 
Kazem et al. (208) 
17 urine samples from immunocompetent 
individuals 
0% 
Scuda et al. (16) 
88 serum samples from immunocompromised 
patients 
0% 
Sadeghi et al. (156) 
621 serum samples from 394 hospitalized elderly 
individuals 
0% 
Kazem et al. (208) 
19 serum samples from immunocompetent 
individuals 
0% 
Scola et al. (165) 193 samples of various skin diseases 0% 
Kanitakis et al. (212) 10 pilomatricoma samples 0% 
Table 3. TSPyV DNA prevalence among non-TS samples. Reproduced with permission from 
Kazem et al. 2013 (208). 
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4. Serodiagnosis  
Serodiagnosis is the process that employs serological testing for diagnosis of diseases.  
The serodiagnostic tools entail the detection and quantification of a specific antibody or 
antigen usually in blood serum samples or in other body fluids such as cerebrospinal fluid 
and saliva. For infectious diseases e.g. caused by viruses, serodiagnostic methods can be 
used to indicate an acute primary infection, to distinguish stages of infection (recent or 
reactivated versus past), or in some cases to assess the efficacy of vaccination or antiviral 
therapy. The classical methods for serological testing include precipitation reaction, 
complement-fixation, hemagglutination inhibition, immunofluorescence, 
radioimmunoassay, Western blot, and enzyme immunoassay (EIA) (214, 215). The 
following chapters focus on the application of antibody detection in the serodiagnosis of 
viral infections.  
4.1 Antibody response in viral infection 
When the host encounters a viral infection, a series of immune responses must in order to 
defend the host against the invading pathogen. For instance, B-cells produce IgM and IgG 
antibodies, which can neutralize the pathogen and serve as markers for the progression of 
infection. Figure 4 shows the classical pattern of antibody response to virus infections. 
Upon primary exposure to the pathogen, a lag phase precedes the appearance of antibodies. 
In the course of primary infection, the first isotype of antibody that appears is IgM, the 
level of which increases rapidly to a plateau and thereafter declines to undetectable levels 
in the following weeks or months. Following IgM, IgG appears due to isotype switching, 
and most often persists in lifelong circulation (216). Once the host encounters the same 
pathogen again, a secondary immune response occurs, sometimes resulting in a detectable 
boost of IgG level, however, as a rule in the absence of IgM (214, 217). Therefore, during 
an acute primary viral infection, it is possible to observe a seroconversion of both virus-
specific IgM and IgG antibodies. 
Notably, one essential feature of the immune response against infection is that the 
avidity of antibodies increases from low to high because of the processes of somatic 
mutation and selection (218-220). Due to pathogen clearance, B-cell clones of higher 
avidity can compete out those of lower avidity, resulting in progressive production of 
higher avidity IgG antibodies (218, 221). Thus, individuals with past immunity usually 
present with high-avidity IgG antibodies already during the acute phase of the reinfection, 
whereas patients undergoing a more recent infection show predominantly low-avidity IgG 
(214). 
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Figure 4 Typical evolution of antibody response following viral infection. 
4.2 EIA for antibody detection 
Because of its capacity of large-scale screening, ease of automation, and high sensitivity, 
EIA is one of the most common serological methods in clinical diagnostic laboratories 
(214, 215). The method involves an enzyme conjugated with an antibody or antigen 
reacting with a substrate to produce color changes, therefore allowing quantitative 
measurement. In serological testing for virus-specific antibodies, three types of EIAs are 
widely utilized: indirect EIA, IgM-capture EIA, and competitive EIA (222).  
In an indirect EIA (Figure 5A), specific antibody in human serum binds to viral 
antigen immobilized on a solid phase. The specific antibody is detected by an enzyme-
labeled anti-human immunoglobulin, of which the enzyme reacts with the substrate to 
generate a color. Depending on the isotype of immunoglobulin, either IgM or IgG  can be 
detected. However, because IgG not only accounts for the majority of immunoglobulins in 
human serum, but also shows higher affinity than does IgM, the prevailing of virus-
specific IgG may interfere with the detection of virus-specific IgM. On the other hand, if 
rheumatoid factor, an IgM-class autoantibody against IgG, is present, a false positive IgM 
result may occur. Thus, IgM-capture EIA is preferred for detection of IgM antibodies in 
clinical samples. In this format (Figure 5B), a repertoire of IgM antibodies are captured 
out of human serum by an anti-human IgM antibody coated on the solid phase. The 
specific IgM is detected by binding to the corresponding antigen preparation. Competitive 
EIA, used to distinguish false positivity, is widely employed when high specificity is 
required. This assay employs a labeled antibody to compete for binding to immobilized 
antigen with antibody in the clinical sample (Figure 5C). Alternatively, soluble antigen is 
used to compete with immobilized antigen for binding to the antibody in the serum (214, 
215, 222). 
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Figure 5 EIA formats. 
Testing for IgG avidity may be accomplished by a modified indirect EIA aiming at the 
distinction between low- and high-avidity bindings. In practice, the reactivity of the serum 
in the well treated with a protein-denaturing agent such as urea that will disrupt the 
antigen-antibody binding, is compared with the reactivity of a well without such treatment. 
If the patient serum has low-avidity IgG, it will be susceptible to the urea treatment. In 
contrast, the high-avidity IgG is more resistant (223). 
4.3 Interpretation of results 
As mentioned, a primary infection can be determined by seroconversion of virus-specific 
IgG or by presence of specific IgM. Usually, a fourfold or more rise in IgG antibody 
concentration between acute and convalescent samples is considered evidence for an acute 
or recent infection. Increasingly, to account for issues such as IgM persistence for a long 
period or short presence, an avidity assay may serve as a more accurate way to determine 
the time of infection. Detection of high-avidity IgG indicates exposure to the virus in the 
past, whereas detection of low-avidity IgG indicates a recent infection. Nevertheless, it 
should be taken into account that the patients  ´ clinical status may affect the results. The 
antibody production may be impaired among the immunosuppressed patients or the 
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elderly, leading to a false negative diagnosis. Transfer of maternal antibodies and cross-
reactive antibodies derived from a recent infection by related pathogens, may lead to false 
information. Overall, essential characteristics of assay performance, referred to as 
sensitivity and specificity, play important roles in result interpretation. The term 
sensitivity refers to the proportion of patients with an infection that test positive, and 
specificity refers to the proportion of individuals without an infection who test negative. 
With antiviral IgM assays, the specificity is critically important, as the presence of 
pathogen-specific IgM antibody is considered a marker of ongoing or recent infection and 
thus affects clinical management (214, 215, 222).  
4.4 Biotinylation-based anti-viral IgM EIA  
Biotinylation is the process of covalently linking biotin to macromolecules, such as 
nucleic acid and protein (224, 225). Biotin is water soluble, and due to its small size, can 
attach to proteins or nucleic acids without changing their natural function (224, 225). The 
interaction between biotin and avidin/streptavidin shows extremely high affinity and 
specificity. Once biotin binds to avidin/streptavidin, it is rarely released by extremes in pH, 
temperature and denaturing reagents (224). Since a number of labeling reagents and 
methods have been developed for biotin, the technique of biotinylation is widely applied 
in biomedical assays (224-228). The biotinylation-based anti-viral IgM EIA is essentially 
an IgM-capture EIA using as antigen biotinylated viral proteins detected by conjugated 
streptavidin (Figure 4A of Study IV). Our lab has employed this method in detection of 
anti-viral IgM for human parvovirus B19 (B19V), parvovirus 4 and human bocaviruses 
(HBoVs) (229-231).   
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AIMS OF THE STUDY 
1. To generate MCPyV and TSPyV virus-like particles (VLPs) in insect cells via the 
baculovirus expression system 
2. To develop for comprehensive serodiagnostic methods of MCPyV and TSPyV 
infections VLP-EIA-based assays for measurement of the respective IgM, IgG and IgG 
avidity 
3. To determine the MCPyV and TSPyV seroprevalences among Finnish adults and 
children 
4. To determine age at and frequency of MCPyV and TSPyV primary infections among 
Finnish children 
5. To determine the clinical pictures of MCPyV and TSPyV primary infections in 
childhood 
6. To assess the occurrence of anti-biotin IgM antibodies in the general population   
7. To assess whether the anti-biotin IgM antibodies exert any adverse effects on 
biotinylation-based anti-viral IgM assays, and the degree of adverse effects on 
different assays 
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MATERIALS AND METHODS 
1. Materials 
1.1 Patients and serum samples  
Children s´ group 1 (Thesis studies: I, II, IV) 
From September 2000 to May 2002, children aged 3 months to 15 years with acute 
respiratory wheezing were admitted to the Department of Pediatrics of Turku University 
Hospital (Turku, Finland). Acute and convalescent phase serum samples were collected at 
the time of hospital admission and 2 weeks later. From a number of children follow-up 
samples were obtained 5-8 years later (232, 233). Study I, for MCPyV, included altogether 
217 children, of which 72 underwent follow-up sampling. Study II, for TSPyV, enclosed 
65 children with both paired acute-phase and follow-up serum samples available. Study IV, 
for biotin IgM, included 366 serum samples obtained from these children. 
Children s´ group 2 (I, II, IV) 
Between March 2001 and December 2002, children aged 1-4 years with recurrent or 
persistent otitis media were randomly selected to undergo adenoidectomy in a clinical 
study trial (234), and the initial serum samples were obtained. An average of three years 
later, these children underwent follow-up sampling. Study I comprised from the clinical 
trial a proportion of 158 children, 86 of which underwent adenoidectomy. Except one 
child with adenoidectomy excluded, Study II and Study IV included the same study 
subjects as Study I. 
Children s´ group 3 (III) 
Since 1994, children have been recruited in the population-based Diabetes Prediction and 
Prevention (DIPP) study for investigation of preclinical events in development of type-1 
diabetes (235, 236). The children were invited for follow-up visits at 3- to 12-month 
intervals, from birth until young adolescence. At each visit, blood samples were collected, 
and the child s´ clinical and physiological data were recorded by a study nurse via parental 
interviewing. Study III comprised from this cohort 144 children, who were born during 
1995-2004 in whom type-1 diabetes did not develop by the end of 2004. These 144 
children were called for an average of 13 visits (median 12, range 8-27), at a mean interval 
of 3.65 months until two years of age, and thereafter of 6.35 months interval. 
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Adult group (II, IV) 
This group comprised 115 university students and 34 staff members of our institute. A 
single serum sample was obtained from each volunteer of normal health. All these 
volunteers were included in Study II, and 144 in Study IV. 
Senior group (IV): 
Senior citizen in-patients of Turku City Hospital participated in the study “Virel” which 
aims to investigate the molecular virus etiology in respiratory diseases in the elderly and 
its links to illness severity and long-term outcome. A total of 468 sera from 316 senior 
citizens (mean age 82 years, range 70-100) were analyzed in Study IV.  
Ethical aspects (I-IV) 
The study protocols were approved by the Ethics Committees of Turku University 
Hospital, Helsinki University Hospital or the Hospital District of Southwest Finland. 
Written informed consent was obtained from all participants. If a senior participant was 
unsure about the consent, a written consent was obtained from the next of kin. For 
participating children, consent was obtained from the corresponding parents or guardians. 
1.2 Plasmids, bacteria and cells (I, II) 
The genes coding for MCPyV VP1 and TSPyV VP1 were chemically synthesized 
(GenScript, USA), and cloned into pUC57 vectors. For improved expression, the codon 
usage was optimized for that of Spodoptera frugiperda (Sf). For MCPyV, the synthesized 
VP1 was based on MCPyV339 (accession number EU375804), and for TSPyV, on the 
reported TSPyV DNA sequence (accession number GU989205). In the Bac-to-Bac 
System (Invitrogen), pFastBacDual vector is used to express two proteins simultaneously, 
and DH10Bac competent cells are used for production of recombinant bacmids. DH10Bac 
contains an AcMNPV parent bacmid that can recombine with a donor plasmid, e.g., with 
pFastBacDual. Sf9 insect cells were used for propagation of the recombinant baculovirus 
and production of recombinant proteins.  
2. Methods 
2.1 Virus-like particle production (I, II) 
VLPs were generated through Bac-to-Bac protein expression system in accordance with 
the manufacturer s´ (Invitrogen) instructions. The VP1 coding sequence was cloned into 
pFastBacDual transfer vector downstream of the polyhedrin promoter and the sequence 
was confirmed. The VP1-containing vector was transformed into DH10Bac to generate 
recombinant baculovirus genomic DNA (bacmid), followed by alkaline-lysis isolation. 
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The recombinant bacmids were transfected into Sf9 cells with cellfectin (Invitrogen). The 
recombinant baculovirus was passaged for two or three times. 
Sf9 cells were infected with recombinant virus at a high multiplicity of infection and 
grown in Insect Express medium (Lonza, Basel, Switzerland) for 4-5 days at 27°C. The 
infected cells were harvested by centrifugation at 1000g for 5 min, washed once with 
phosphate-buffered saline (PBS), suspended in lysis buffer 1 (20mM Tris-HCl, pH 7.5; 
150mM NaCl; 1% Triton) and kept on ice for 10 min, followed by centrifugation at 
10,000g for 10 min. Then, the pellet was resuspended in lysis buffer 2 (10mM Tris-HCl, 
pH 8.0; 500mM NaCl; 1mM CaCl2; 1mM MgCl2; 0.01% Triton) supplemented with a 
protease inhibitor cocktail (complete EDTA-free; Roche). After sonication on ice, the 
lysate was collected by centrifugation at high speed, 12,000 -13,000 rpm, for 3 -10 min, 
and applied to CsCl gradient ultracentrifugation. 
Two types of CsCl gradient were employed. In Study I, 1 ml of lysate preparation was 
loaded on the top of 11 ml of 28% CsCl, and centrifuged in a Beckman SW40Ti rotor at 
24,200 rpm at 4°C for 48h. The fractions containing visible bands were collected. In Study 
II, 3.5 ml preparation was loaded on a 1.5-ml of a 25% (wt/vol) sucrose shelf (in 20mM 
Tris, pH 7.5), and centrifuged in a Beckman SW55Ti rotor at 103,246×g at 4°C for 2h. 
The pellets containing partially purified VLPs were resuspended in 400µl 20mM Tris (pH 
7.5), and loaded on top of a 1.23 to 1.36 g/cm
3
 CsCl gradient. After ultracentrifugation in 
a Beckman SW55Ti rotor at 103,246×g at 4°C for 15h, the upper 2ml of the gradient was 
removed, and 250µl fractions were collected.  
The VLP-containing fractions were determined by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE), and the presence of VLPs was 
confirmed by EM. The fractions were dialyzed against PBS three times over night. The 
VLPs in PBS were supplemented with NaN3 (final concentration of 0.05%) and stored at 
4 °C. The protein concentration was measured by BCA Protein Assay kit (Pierce). 
2.2 Biotinylation (I, II, IV) 
Biotinylation of protein were performed by using the EZ-LinkSulfo-NHS-LC-
Biotinylation kit in accordance to the manufacturer s´ (Pierce) instructions. The target 
protein  VLPs in Studies I and II, and bovine serum albumin (BSA) (Sigma-Aldrich, 
A7906) in Study IV  in PBS (approximately 1mg/ml) were incubated with 30-fold molar 
excess of biotin at room temperature (RT) for 1 hour. The biotinylated products were 
dialyzed against PBS three times over night. 
2.3 Immunoblotting (I, II, IV) 
In Studies I and II, dot blotting was employed. The nitrocellulose membranes (Whatman 
Protran BA 85) spotted with 1-2µL of protein were blocked in 5% BSA in Tris buffered 
saline with 0.1% Tween 20 (TBS-T) for 30 min at RT. Serum samples diluted in 0.1% 
BSA/TBS-T were put onto the membranes for 30 min. The secondary antibody, 
horseradish peroxidase (HRP)-conjugated anti-human IgG (DakoCytomation, Denmark) 
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diluted 1:1000 in 5% BSA/TBS-T was added to the membrane and kept for 30 min. The 
bound antibody was visualized with 3,3 -´diaminobenzidine and H2O2. To detect 
biotinylated VLPs in Study I, the blocked membranes were incubated with HRP-
conjugated streptavidin (Dako, Glostrup, Denmark) at 1:10,000 in 5% BSA/TBS-T and 
visualized as above.  
In Study IV, Western blot was employed. Biotinylated BSA (bio-BSA) or BSA loaded 
at 1µg/lane was separated by SDS-PAGE. After transferred onto nitrocellulose membranes, 
the membrane was blocked in 5% BSA in TBST for 30min at RT. The serum samples 
diluted in 5% BSA/TBST were applied on the blots at 4°C overnight. The secondary 
antibody, HRP-conjugated rabbit anti-human IgM (DakoCytomation, Glostrup, Denmark) 
diluted 1:20,000 in 5% BSA in TBST was applied for 1 hour at RT. The blots were 
visualized using the SuperSignal West Dura Extended Substrate Detection kit (Pierce, 
Rockford, IL.) and exposed on X-ray films (Fuji Super RX). 
2.4 In-house antibody assays (I-IV) 
Virus-specific IgG EIAs (I-IV) 
The biotinylated VLPs, serving as antigen, were diluted in PBS containing 0.05% Tween 
20 (PBST) to a final concentration of 60ng/100µl. Then, 100 µL of antigen preparation 
were added to each well of streptavidin-coated plates (Thermo Scientific) followed by 
incubation for 60 min at RT in a rocking (400 rpm) EIA incubator. To minimize 
nonspecific background, the antigen-coated plates were post-blocked with sample diluents 
(three times, 10 min each). The serum samples diluted 1:200 were applied (100µl/well) for 
60 min as the above. After washes with PBST (three times, 5 min each), HRP-conjugated 
rabbit anti-human IgG diluted 1:2,000 in the sample diluents, was added to each well 
(100µl/well), and incubated for 60 min as the above. After washes with PBST (four times, 
5 min each), orthophenylene diamine (OPD) and H2O2 were added and incubated at RT. 
After 15min, 0.5 M H2SO4 was added to stop the reaction, and the absorbances at 492 nm 
were recorded.  
Virus-specific IgM EIAs (III, IV) 
With virus-specific IgM EIA, a µ-capture format was employed. A polyclonal goat anti-
human IgM antibody (Cappel/ICN Biomedicals) diluted 1:1200 in 50mM carbonate buffer, 
pH 9.6 (Sigma). Preparations were added (100µl/well) to each well of a microtiter plate 
and incubated at RT overnight. On the next day, the plate was rinsed with PBST (five 
times), followed by incubation with 150 µl of 3% BSA in PBS for 30 min at 37 °C. After 
a rinse, the pre-coated plate can be stored at 4 °C for up to one month. The human serum 
samples diluted 1:200 in PBST were applied at 100µl/well to the pre-coated plate and 
incubated for 60 min at RT in the EIA incubator. After rinses with PBST (five times), the 
plates were applied with the preparation of detection antigen and incubated for 45 min at 
37 °C. The biotinylated MCPyV and TSPyV VLPs were prepared in 0.5% BSA in PBST 
at a concentration of 10ng/100µl. After rinses with PBST (five times), the plates were 
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treated (100µl/well) with HRP-conjugated streptavidin (Dako, Glostrup, Denmark) diluted 
1:12,000 in 0.5% BSA in PBST for 45 min at 37°C, followed by OPD and H2O2 for 15 
min at 37°C.     
IgG avidity EIAs (III) 
The IgG-avidity EIA was based on the IgG EIA described above. However, two additional 
steps were included: (i) From the serum two dilution series in PBST were made at fourfold 
steps  one from 1:50 to 1:3200 and the other from 1:200 to 1:12,800. (ii) After antibody 
binding, the microwells of the former series were washed with urea in PBST, whereas, 
those of the latter series were washed with PBST alone. Thus, two dilution curves and 
IgG-end-point titers were obtained. Their ratio was calculated with curve-fitting software, 
representing IgG avidity (237). 
Biotin IgM indirect EIA (IV) 
The Bio-BSA prepared in PBS at a concentration of 200ng/100µl was added (100µl/well) 
to microtiter wells (Nunc-Immuno™ Modules), and incubated for 2.5 hours at 37°C. After 
rinses with PBST (five times), the plates were blocked (150µl/well) in 5% BSA in PBS for 
30 min at 37°C. After a rinse with PBST, the pre-coated plate can be stored at 4 °C for one 
day. The serum samples diluted 1:100 in PBST were applied (100µl/well) for 60 min at 
RT in the EIA incubator. The secondary antibody, HRP-conjugated rabbit anti-human IgM 
diluted 1:1,000 in 3% BSA in PBST, was added (100µl/well), and incubated for 60 min as 
above. After washes, OPD and H2O2 were added RT, and the reaction was stopped after 
25 min. 
2.5 Cutoff determination (I-IV) 
For virus-specific IgG EIA (I, II), cutoff values were determined as follows: (i) the 
absorbance values from lowest to highest were placed in a dot plot, yielding a polynomial 
fit curve; (ii) a provisional cutoff was determined by visual inspection of the fitting curve; 
(iii) values below the provisional cutoff were used to calculate their mean and SD; (iv) the 
exact positions of the cutoff were determined by competition of serum samples spanning 
an absorbance range of 0.05 to 0.500. Two cutoffs were set for each assay. Samples with 
absorbance values exceeding the higher cutoff were considered virus-specific IgG positive, 
and samples with values below the lower cutoff were considered negative. With the 
samples of absorbance values between the two cutoffs, competition assays were performed 
to determine unequivocal positivity or negativity. 
In Study I, a specific MCPyV-IgG signal was obtained by subtraction of the antigen-
free background in the MCPyV EIA. The higher and lower cutoffs were 0.120 and 0.150. 
In Study III, subtraction of the antigen-free background was omitted, and the two cutoffs 
were adjusted to 0.120 and 0.210. With TSPyV IgG EIA, the cutoffs were 0.100 and 0.240. 
For the virus-specific IgM EIA (III), the cutoff was calculated from 40 serum samples 
of adults with serological evidence for past infection with the virus (Methods in Study III). 
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The cutoffs for MCPyV IgM EIA were 0.207 and 0.260, and the cutoffs for TSPyV were 
0.194 and 0.240. 
For Bio-EIA (IV), the cutoffs were determined in accordance with the WB results 
(Methods in Study IV).  
2.6 Affinity determination (IV) 
Based on the Biotin IgM indirect EIA, a competition assay was set up to measure biotin 
IgM affinity. The serum samples were incubated with increasing concentrations of soluble 
biotin (Sigma-Aldrich, B4501) over night. On the next day, the mixtures were applied 
onto Bio-EIA plates and the amount of antibody bound to the solid phase was measured. 
The absorbance values were plotted to yield a fitting curve by a nonlinear regression 
program (GraphPad Prism). The affinity was then calculated from the curve. 
2.7 Quantitative PCR (III) 
The DNA in 30µL of serum was extracted by phenol-chloroform, precipitated by sodium 
acetate and ethanol, eluted in 30µL of 10mmol/L Tris-Cl buffer (pH 8.0) and stored at -
20°C. An amount of 5µL was applied in quantitative PCR (qPCR). The MCPyV LT gene-
based qPCR and TSPyV LT gene-based qPCR were performed as described (156) with a 
Stratagene Mx3005p instrument (Agilent Technologies, Santa Clara, CA, USA).  
2.8 Statistical analysis (I-IV) 
The seroprevalence and seroconversion rate differences between males and females were 
compared by logistic regression (I, II). Absorbance values of two groups were compared 
by a non parametric Mann-Whitney test with the tied P-value (I). Liddell s´ exact test was 
employed to compare infection-related symptoms in each child during the seroconverted 
interval with symptoms during the previous sample interval and the subsequent interval 
(III). Wilcoxon rank-sum test, Spearman Correlation and Logistic regression, were 
employed to analyze whether the children experienced illness during the seroconversion 
period associated with background factors of the child, which were detailed in Study III. 
Absorbance values of more than two groups were analyzed using one-way ANOVA for 
overall comparison, followed by Tukey-Kramer HSD test for pairwise comparison (IV).  
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RESULTS  
1. MCPyV and TSPyV serodiagnostics and infections 
1.1 Virus-like particles (I, II) 
For generation of VLPs of MCPyV and TSPyV, the synthetic viral VP1 genes were cloned 
into a recombinant baculovirus and expressed in Sf9 cells. By SDS-PAGE, a major protein 
band was seen in the whole cell lysates, and in the CsCl gradient-purified material. When 
fractionally purified by the two-step method, the VLPs of both MCPyV and TSPyV were 
barely seen in the cytosolic lysates, whereas they were highly enriched in the nuclear 
lysates (Fig. 1 of Study I and Figure 6). By EM, the purified VLPs had an icosahedral 
shape (Fig. 2 of Study I and Figure S1A of Study II).  
 
Figure 6 SDS-PAGE of TSPyV VP1 in cell lysates and VLPs after purification and enrichment 
of TSPyV VP1 in nuclear lysate. Sf9 cells were harvested 3 or 4 days postinfection 
and processed by two-step lysis. As a control, GST was expressed in Sf9 cells by the 
same procedure. Whole: the whole cell lysate. Lys1: the supernatant of first lysis 
(cytosolic lysates). Lys 2: the supernatant of second lysis (nuclear lysates). Purified: 
Purified TSPyV VLPs after CsCl ultracentrifugation, arrow: TSPyV VP1; arrow head: 
Glutathione S-transferase (GST). 
 1.2 Antibody responses (I-III) 
MCPyV and TSPyV IgG EIAs were set up by using VLPs as antigen, to detect antibody 
responses against the capsid protein VP1. The IgG EIA reactivities among each group are 
shown in Figure 7A. Of 1749 serum samples tested by MCPyV IgG EIA (Figure 7B), 66% 
were shown with absorbance values below 0.1 OD units, 20% with OD between 0.1 and 
1.0, 9% with OD between 1.0 and 2.0, and 4% with OD exceeding 2.5. Of 1316 serum 
samples tested respectively by TSPyV IgG EIA, 65%, 9%, 13% and 13% were shown.  
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Figure 7 (A) Distributions of MCPyV and TSPyV seroreactivities. GR_CH1.1: the initial serum 
samples obtained from the children s´ group 1. GR_CH1.2: the 5-8 year follow-up 
serum samples obtained from the children s´ group 1. GR_CH2.1: the initial serum 
samples obtained from the children s´ group 2. GR_CH2.2: the 3-year follow-up 
serum samples obtained from the children s´ group 2. GR_CH3: the serum samples 
obtained from the children s´ group 3. GR_AD: the serum samples obtained from the 
adult group. Line indicates higher cutoff in the corresponding assay. (B) The bar 
chart with percentage of 1749 serum samples at the various ODs in MCPyV EIA and 
1316 serum samples in TSPyV EIA. 
In Studies I and II, immunoreactivities of MCPyV and TSPyV VLPs with human IgG 
were examined by dot-blotting. The EIA-seropositive samples with high to low 
absorbance values showed corresponding reactivity with the native VLPs, but little or no 
reactivity with the same VLPs that had been pre-denatured (Fig. 3 of Study I and Figure 2 
of Study II). 
To assess the degree of antigenic cross-reactivity between TSPyV and MCPyV VLPs, 
sera that were EIA-seropositive for both TSPyV and MCPyV were applied in competition 
assays. In TSPyV EIA, the seroreactivities decreased to undetectable level when the serum 
was preincubated with unbiotinylated TSPyV VLPs, but not with MCPyV VLPs. 
Conversely, their reactivities in MCPyV EIA declined to undetectable level by MCPyV 
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VLPs, but not by TSPyV VLPs. The antibody reactivities of adult sera showed no 
correlation between TSPyV and MCPyV VLP EIAs (Figure S2 of Study II).  
In Study III, for each seroconverting child, the antibody responses including IgG, IgM 
and IgG avidity, of the consecutive serum samples are shown in a line graph (Supplement 
1 of Results). The MCPyV IgM and IgG antibodies occurred in five patterns among the 45 
MCPyV seroconverting children (Supplement 2 of Results and Figure 2 of Study III): IgG 
seroconversion without IgM detectable in 28 (62%), or with IgM transiently present in 11 
(24%), IgM detectable before IgG in 4 (9%), transient IgM re-occurring after reversion of 
the initial IgM in 2 (4%), and persistence of IgM till the end of follow-up in 1 (2%). 
Among 39 TSPyV seroconverting children, four patterns were seen (Supplement 2 of 
Results and Figure 2 of Study III): IgG seroconversion without IgM detectable in 9 (23%), 
or with IgM transiently present in 28 (72%), transient IgM re-occurring after the initial 
IgM in 1 (3%), and persistence of IgM till the end of follow-up in 1 (3%).  
From each seroconverter who had at least two follow-up visits after seroconversion, 
three serum samples  one taken at the IgG-seroconversion visit, one at the subsequent 
visit, and one at the last visit, were analyzed for IgG avidity (Supplement 2 of Results and 
Supplementary Figure of Study III). Among 33 such MCPyV seroconverters, 22 showed 
maturation of IgG avidity from low or borderline to high during the follow-up, 7 showed 
consistent high avidity, and 4 showed consistent low avidity. Of 27 such TSPyV 
seroconverters, 14, 12 and 1 showed the respective avidity patterns. The sampling 
intervals are shown in Supplementary Figure of Study III. 
1.3 Seroprevalences (I-III) 
Among the children s´ group 1 (Table 4), 217 children were studied for MCPyV IgG. The 
MCPyV IgG seropositivities increased from 4% among children less than 1 year of age to 
35% at 4-13 years. Among the children who underwent follow-up sampling 5-8 years later 
at 6-11 years of age, 37% were seropositive for MCPyV IgG. Of note, among the 65 
children who were in the first samples seronegative, 22 (33 %) seroconverted for MCPyV 
during the 5-8-year follow-up. Of the same children s´ group, 65 were studied for TSPyV 
IgG. Among the children below 1 year of age, 10% were TSPyV IgG positive, and at 1-3 
years of age, 7% were. After a follow-up of 5-8 years, of initially TSPyV-seronegative 
children 45% experienced a seroconversion. The seropositivity increased to 48% among 
children at 6-11 years of age. 
Among the children s´ group 2 (Table 4), 158 children were studied for MCPyV IgG. 
At the initial sampling (at 1-3 years of age), 4% were seropositive, while at 3-year follow-
up, 18% were (at 4-7 years of age). Of the initially seronegative children, 16% 
seroconverted for MCPyV during an average of 3 years. Among the same children group, 
157 children were studied for TSPyV IgG. At the initial sampling, 5% were seropositive, 
while at the follow-up, 34% had IgG antibodies in their sera. Of the initially TSPyV 
seronegative children, 30% seroconverted. 
Among the children s´ group 3 (Table 4 and Figure 1 of Study III), the MCPyV 
seroprevalence increased from 12% at 1-2 years of age to 45% at 6-13 years of age, while 
the TSPyV seroprevalence increased from 3% to 39%. Of 144 children, 45 showed IgG 
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seroconversion by MCPyV and 39 by TSPyV. Of these seroconverters, four children 
showed IgG seroconversion with MCPyV during infancy, and one with TSPyV, while one 
child showed MCPyV IgG, IgM and low avidity of IgG in the first sample at infancy. 
In Study III, the respective maternal IgG for MCPyV and TSPyV was seen in 22% 
(10/45) of MCPyV seroconverters and 31% (12/39) of TSPyV seroconverters at sampling 
ages of 0.23-0.62 year, and these maternal IgGs disappeared by 0.49-1.07 year.  
Table 4. Seroprevalence among the children s´ groups. 
Among the adult group, of 115 volunteers who were studied for MCPyV IgG, 53% 
were seropositive, whereas of 149 volunteers studied for TSPyV IgG, 70% were 
seropositive.  
1.4 Asymptomatic MCPyV and TSPyV primary infections among children (III)   
Of 45 MCPyV seroconverting children, 62% showed serological markers of primary 
infection, other than IgG seroconversion: 33% showed the presence of IgM antibodies and 
51% showed low-avidity of IgG (Table 5). Of 39 TSPyV seroconverting children, 82% 
showed these acute-phase markers: 77% IgM antibodies and 33% low-avidity IgG. Co-
presence of IgM antibodies and low-avidity of IgG were seen in 22% of the MCPyV 
seroconverters, and in 28% of the TSPyV seroconverters. MCPyV viremias were found 
neither in the IgG seroconversion samples, nor in the previous or subsequent samples. 
TSPyV viremias were observed at low quantity in the IgG seroconversion samples of two 
children at 4.5 and 3.0 years of age. 
 Children s´ group 1  Children s´ group 2  Children s´ group 3 
Age MCPyV TSPyV Age MCPyV TSPyV Age MCPyV TSPyV 
<1y 
2/51 
(4%) 
2/20  
(10%) 
      
1-4y 
7/79  
 (9%) 
3/45  
 (7%) 
1-3y 
6/158 
(4%) 
8/157 
(5%) 
1-2y 
17/144 
(12%) 
5/144 
(3%) 
2-3y 
26/144 
(18%) 
8/144 
(6%) 
3-4y 
31/142 
(22%) 
18/142 
(13%) 
4-13y 
9/26 
(35%) 
 4-7y 
28/158 
(18%) 
53/157 
(34%) 
4-5y 
25/111 
(22%) 
21/111 
(19%) 
5-6y 
18/75 
(24%) 
21/75 
(28%) 
6-11y 
26/71 
(37%) 
31/65 
(48%) 
   6-13y 
23/51 
(45%) 
20/51 
(39%) 
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No. (%) 
children  
MCV Virologic findings  Mean  Median  Range  
15 (33) IgM antibodies, abs  0.394  0.285  0.213–1.080  
0 (0)  qPCR positive  
   
23 (51)  low IgG avidity, %  10.1  10.3  1.9–15.0  
10 (22)  IgM together with low IgG avidity  
     
No. (%) 
children  
TSV Virologic findings  Mean  Median  Range  
30 (77)  IgM antibodies, abs  0.447  0.405  0.197–0.851  
2 (5)  qPCR positive  Low positivity Ct 35.4 and 39.6  
13 (33)  low IgG avidity, %  8.8  7.9  1.1–15.0  
11 (28)  IgM together with low IgG avidity 
2 (5)  IgM together with qPCR positive  
Table 5. Serologic findings among MCPyV and TSPyV seroconverters. 
For determination of any possible clinical correlates during MCPyV or TSPyV 
primary infections, all infection-related symptoms and illnesses during the seroconversion 
interval were compared with those during the previous or the subsequent interval for each 
IgG-seroconverted child. Symptoms and signs of infection-related illness during the 
seroconversion interval were reported in 73% MCPyV seroconverters and in 82% TSPyV 
seroconverters. Neither the overall symptoms nor any individual symptom significantly 
differed from those of the previous and subsequent intervals (Table of Study III).  
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2. Biotin IgM antibodies 
2.1 Observation of false MCPyV IgM positivity due to biotin antibody 
In the in-house MCPyV IgM µ-capture EIA, high reactivity was seen in one serum sample 
originating from our staff (designated #m22), which was also positive for MCPyV IgG. 
Another serum sample obtained from the same individual one year earlier was found 
positive for MCPyV IgG, but negative in the MCPyV IgM assay. In dot blotting for the 
MCPyV IgM antibodies, the sample #m22 was reactive with biotinylated but not with 
non-biotinylated MCPyV VLPs (Figure 8). Similarly, in Western blot, the sample was 
reactive with biotinylated but not with nonbiotinylated BSA, and furthermore in a 
competition assay the reactivity was reduced dose-dependently by increasing amounts of 
soluble biotin (Figure 8). These observations demonstrated in this human serum the 
occurrence of anti-biotin IgM antibodies, which caused false positivity in a biotinylation-
based antiviral IgM assay. 
 
Figure 8 In dot blotting, serum sample #m22 reactive with biotinylated antigens but not with 
the non-biotinylated one. In Western blot, the IgM reactivity was reduced when the 
serum was co-incubated with 0µg/ml, 10µg/ml and 100µg/ml of competition soluble 
biotin. First on the right side is the blot treated with the protein stain Ponceau S red.  
2.2 Seroprevalence of biotin IgM 
A bio-EIA using biotinylated BSA as antigen was then developed, to determine the 
occurrence of biotin IgM antibodies in the general population. The EIA OD values of 612 
serum samples from 459 adults are shown in Figure 1 of Study IV. In accordance with 
Western blot results (Figure 2 of Study IV), in this bio-EIA the cutoff for IgM positivity 
was set at 0.3 OD units. Among 144 adults, 4 (2.8%) had biotin IgM, and among 316 
senior citizens 10 (3.2%) were biotin IgM-positive. The donor #22 who was initially 
positive lost his IgM during follow-up of six months, without any detectable anti-biotin 
IgG. Among 678 samples from 349 children aged 1-12 years, only one was positive. 
Overall, the seroprevalence of biotin IgM among adults was 3.0%, and among children 
0.3%. 
2.3 The effect of biotin antibody on various IgM-antibody assays 
We then assessed the frequency of adverse-effects of the biotin IgM on various 
biotinylation-based antiviral IgM assays of µ-capture format, including four inhouse virus 
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IgM EIAs (MCPyV, TSPyV, HBoV1, B19V) and one commercial kit (B19V EIA of 
Biotrin). The results are shown in Figure 3 of Study IV and Table 6. Of note, all the four 
samples with Bio-EIA reactivities above OD 3, showed high reactivities in all these five 
assays. Among 20 serum samples positive for biotin IgM, the numbers of respective 
samples that were positive, negative, and at borderline range in each antiviral IgM assay 
were 17, 3, 0 in inhouse MCPyV EIA, 7, 11, 2 in TSPyV, 4, 16, 0 in HBoV, 7, 12, 1 in 
B19V (inhouse), and 1, 18, 1 in B19 Biotrin EIA (Table 6). 
2.4 Characteristics of Biotin IgM 
Bio-IgM positive and negative samples were applied in a µ-capture EIA (Figure 4 of 
Study IV), and tested with one of three different antigens: biotinylated VLPs, biotinylated 
BSA and soluble biotin. Bio-IgM-positive samples showed positive IgM results with 
biotinylated VLPs at a minimum amount of 5ng/well, with biotinylated BSA at a 
minimum amount of 10µg/well, while yielded negative results with soluble biotin 
irrespective of amount applied. In competition assays in a µ-capture IgM EIA (Figure 5 of 
Study IV), the reactivities of two Bio-IgM-positive sera were blocked dose-dependently 
by increasing concentrations of soluble biotin, but not by non-biotinylated MCPyV VLPs. 
Conversely, with two MCPyV-IgM-positive sera, the reactivities were blocked by 
MCPyV VLPs, but not by biotin. The binding of bio-IgM to biotinylated BSA was 
inhibited by biotin, but not by vitamin B5, with IC50s ranging from 2.1×10
-3
 to 1.7×10
-4
 
mol/L. 
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Subject # 
Bio-IgM 
EIA 
Inhouse IgM EIAs Commercial 
B19 biotrin 
EIA MCV TSV Boca B19 
107.1 0.312 0.205 0.190 0.021 0.070 0.086 
107.2 0.379 0.203 0.185 0.021 0.130 0.093 
191.1 0.525 0.269 0.092 0.053 0.105 0.115 
191.2 0.438 0.202 0.069 0.042 0.095 0.118 
199 0.420 0.378 0.045 0.024 0.096 0.081 
250.1 0.323 0.437 0.338 0.049 0.280 0.111 
250.2 0.360 0.480 0.295 0.064 0.269 0.085 
304 0.429 0.344 0.327 0.033 0.103 0.080 
312 0.434 0.674 0.156 0.030 0.151 0.102 
343 0.345 0.315 0.141 0.043 0.309 0.101 
400 0.401 0.429 0.118 0.036 0.074 0.080 
54 0.529 0.284 0.209 0.029 0.066 0.105 
61 0.512 0.525 0.108 0.021 0.070 0.094 
13.1 1.004 0.420 0.141 0.013 0.171 0.079 
13.2 0.887 0.427 0.148 0.027 0.174 0.078 
28 1.118 0.547 0.227 0.072 0.146 0.171 
 > OD 3.0     
08PR2372 3.570 1.224 0.621 0.345 0.633 0.316 
08PR2450 3.503 0.822 0.520 0.205 0.415 0.217 
06PR384 3.445 1.766 0.328 0.212 0.861 0.434 
88 3.299 1.846 0.843 0.222 1.289 0.172 
Table 6. Effects of biotin IgM on various anti-viral IgM assays. Bold: positive in the 
corresponding IgM EIA. Underline: at the borderline zone of the IgM EIA. 
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DISCUSSION 
1. MCPyV and TSPyV serodiagnostic assays (I-III) 
1.1 Generation of MCPyV and TSPyV VLPs 
For use as antigens in antibody assays, we generated for MCPyV and TSPyV the 
corresponding VLPs by expression of virus capsid protein VP1 in insect cells. 
Recombinant MCPyV and TSPyV VLPs have been reported in several independent 
studies, either by a similar methodology as ours or by co-expression of MCPyV VP1 and 
VP2 in eukaryotic cells (123-126, 129). The fact that MCPyV and TSPyV VP1 self-
assembled into VLPs without requirement of the minor proteins VP2 and VP3 is 
analogous to those reported with the classical polyomaviruses  SV40, BKPyV and 
JCPyV (25, 26, 238-241). It is thought that VP2 and VP3 are required in encapsidation of 
DNA to form infectious virions, but not compulsory for formation or stability of viral 
capsids (117).  
The nuclear localization signal of VP1 of JCPyV and BKPyV has been identified. 
JCPyV or BKPyV VP1 are expressed in the cytoplasm of insect cells and transported to 
the nucleus for VLP assembly (26, 238). We purified the VLPs of MCPyV and TSPyV by 
two-step lysis to separate the cytosolic and nuclear fractions, and found the VLPs to be 
highly enriched in the nuclear lysates. Thus, these two new viruses are assembled in the 
nuclei, similar to the classical HPyVs. Indeed, the basic sequence (MAPKRKASSTCK) at 
the N terminus of MCPyV VP1 and the one (MAPKRKGEGCA) at TSPyV VP1, 
resemble the nuclear localization signals in VP1 of JCPyV (MAPTKRKGERKD) or 
BKPyV (MAPTKRKGECP) (26, 238). Evidently, in both MCPyV and TSPyV, VP1 alone 
contains sufficient structural information for viral capsid formation. 
The conformation dependence of antibody reactivity has been reported with BKPyV 
and JCPyV (26, 238, 242). We assessed the nature of capsid epitopes of MCPyV and 
TSPyV, and found them, likewise, to be conformational rather than linear. A similar 
conclusion with MCPyV was reached by peptide library screening and Western blotting 
(126). Of note, studying BKPyV and JCPyV epitopes with monoclonal antibodies, 
Randhawa et al. showed that antibodies reacting with intact VLPs recognized 
conformational epitopes located on exposed surfaces of VLPs, whereas antibodies reactive 
with disrupted VLPs recognize linear epitopes buried inside (243).  
1.2. Serodiagnostic tools for MCPyV and TSPyV 
In the Studies I and II, EIAs were developed to detect antibodies for the two recently 
found HPyVs. For SV40, JCPyV, and BKPyV, a variety of antibody assays have been set 
up, such as immunoblotting, hemagglutination inhibition assay, EIA, neutralization assay, 
complement fixation, and immunofluorescence assay (244). However, for the newly 
detected HPyVs, the serological assays developed thus far have been EIA-format or 
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Luminex-based (122, 127, 239, 245, 246). The antigens have been either VP1 capsomers 
or VLPs (122-126, 245). However, since self-assembled VLPs morphologically resemble 
native viral particles and thus retain the conformational epitopes, VLP-based EIAs are 
likely to be more sensitive than the VP1-capsomers based (193, 238, 242). Neutralization 
assay, identifying protective antibodies, have not been widely applied for the newly found 
HPyVs, apparently due to the lack of permissive cell lines for infection by these viruses. 
For MCPyV, an alternative format of neutralization assay has been set up with a reporter-
gene-enclosed pseudovirus (115).  Other than viral capsid protein VP1, HPyV LT has also 
been investigated as serodiagnostic antigen (131, 242, 247). Compared to anti-VP1 
responses, the antibody responses against BKPyV LT have been found to occur at lower 
frequency and at lower level, and to be associated with more extensive BKPyV replication 
after primary exposure (242). With MCPyV, anti-LT antibodies are shown in 40% of 
MCC patients but only in 0.9% of healthy controls (131). These findings suggest that anti-
LT antibody is not an appropriate indicator for an early exposure of HPyVs, but may serve 
as serological markers for extensive viral replication, such as viral reactivation. 
For diagnosis of primary infections by MCPyV and TSPyV, in addition to assays for 
viral IgG, we set up EIAs for viral IgM and IgG avidity. As noted, both presence of IgM 
and low avidity of IgG are serological markers for an acute infection. In Study III, we 
investigated the occurrences of these two markers post-IgG seroconversion among 
children followed up prospectively for MCPyV or TSPyV, and observed these two in 
more than half of IgG-seroconversion samples for each virus. Of the two markers, 
presence of IgM was more frequent than presence of low-avidity IgG among TSPyV 
seroconverters, whereas presence of low-avidity IgG was frequent among MCPyV 
seroconveters. This might suggest some difference in immunoglobulin class shift or 
affinity maturation for these new HPyVs. Regarding viremia, MCPyV DNA was absent 
from all the samples at or flanking the IgG seroconversions, while TSPyV DNA was seen 
at low copy number in two seroconverters. In Tolstov s´ study on adult seroconverters, 
MCPyV viremia was neither found (194). These observations suggest that MCPyV or 
TSPyV may not be viremic or that viremia is of short duration. Thus, serodiagnosis is 
likely to be the approach of choice in diagnosis of primary infection both for MCPyV and 
TSPyV.  
The cutoffs, used as criteria for positivity and negativity, crucially affect the sensitivity 
and specificity of diagnostic assays. In general, serodiagnostic cutoffs should be 
determined using subjects with or without defined infection (222). In the absence of such 
standards, we determined the cutoffs via statistical calculation of potential 
negative/positive results obtained through visual observation of EIA results from a large 
number of samples. To limit false results, we employed a broad borderline zone between 
the higher and lower cutoffs, and samples yielding results in this zone were further 
examined with VLP competition.  
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2. MCPyV and TSPyV infections (I-III) 
2.1 MCPyV and TSPyV antibody responses and seroprevalence  
We found among Finnish adults MCPyV VP1 seroprevalence of 57% and TSPyV VP1 
seroprevalence of 70%, which is in line with the seroprevalence of the classical HPyVs 
among European and US populations. The seroprevalence for the other known HPyVs are 
80-100% for BKPyV, 40-70% for JCPyV, 70-100% for WUPyV, 55-90% for KIPyV, 70-
80% for HPyV6, 35-60% for HPyV7, 30- 50% for HPyV9, and 20% for HPyV12 (43, 122, 
123, 246, 248-252). For MCPyV, seroprevalence of 50-95% have been reported in adults 
of different geographical regions (115, 122-127, 194), while for TSPyV, seroprevalence of 
70% and of 76% were reported in Dutch and Italian cohorts, respectively (123, 245). The 
high seroprevalence of these two recently detected HPyVs among asymptomatic adults 
indicate that infections with MCPyV or TSPyV are common in the general population. 
In three different Finnish pediatric study cohorts, MCPyV seroprevalence was 9-45% 
and TSPyV was 7-48% among children at 1-13 years of age, consistent with prior and 
subsequent reports on the presence of MCPyV and TSPyV IgG in childhood. MCPyV 
seroprevalences among children as reported by Kean et al. were 20.5% at 1-5 years, by 
Tolstov et al. 43% at 2-5 years, by Viscidi et al. 45% under 10 years, and by Nicol et al. 
58% under 10 years (122, 123, 125, 126). The TSPyV seroprevalences in childhood as 
reported by van der Meijden et al. were 41% under 9 years of age, and by Nicol et al., 31% 
at 1-4 year and 70% at 5-9 years (123, 245). Concerning pediatric infections by other 
HPyVs, the JCPyV seroprevalence reaches approximately 25% in young adolescence 
whereas BKPyV seroprevalence reaches up to 90% among children under 10 years of age 
(43, 248). The rates of seropositivity for both WUPyV and KIPyV increase rapidly among 
children of 4-6 years, reaching 87 % and 93%, respectively (250). 
In Study III, the average seroconversion age for MCPyV was slightly lower than for 
TSPyV, whereas the seroprevalence among adults of TSPyV was higher than of MCPyV, 
suggesting that the transmission routes of these two viruses might differ. A feco-oral route 
has been proposed for MCPyV, effected via skin contact or saliva (15, 143, 153, 253, 254). 
A quite recent study demonstrated that MCPyV infection is acquired through close contact, 
especially between siblings and between mothers and their children (255). Furthermore, 
the number of children experienced MCPyV infection during infancy is higher than that of 
TSPyV, suggesting that MCPyV shedding from maternal skin may affect infection.   
We conducted follow-up studies in these three pediatric populations, in order to get a 
clearer idea about time and frequency of primary infections with MCPyV and TSPyV. 
With MCPyV, 33% of children seronegative at < 3 years of age were shown to 
seroconvert during 5-8 years, 16% of children seronegative at 1-4 years to seroconvert 
during an average of 3 years, and 31% of children followed from birth up to 13 years of 
age to seroconvert during the follow-up. With TSPyV, among these three cohorts the 
corresponding seroconversion rates were 45%, 30% and 27%. In addition to high 
seroprevalence, these observations on seroconversion further provide evidence that the 
primary exposures to these two newly found HPyVs occur extensively in early childhood.  
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BKPyV antibody titers and seroprevalences decrease with increasing age, while those 
of JCPyV remain relatively unchanged or may increase (43, 248). For both MCPyV and 
TSPyV, we observed in a substantial proportion of seroconverting children in Study III the 
occurrence of maternal antibodies. These maternal antibodies mostly declined to 
undetectable level by the end of the first year of age. In contrast, the MCPyV and TSPyV 
IgG, acquired through infection, can persist long. From all of the seroconverting children, 
IgG antibodies were detectable until the end of follow-up. Interestingly, we observed in 
one fourth of the MCPyV seroconverters a further increase in antibody level after 0.8-3.0 
years. This booster of IgG response is apparently due to antigenic re-stimulation, as 
MCPyV DNA is widely shed in human skin (15, 129).  
To date, the antigens used in MCPyV serological assays are derived from two MCPyV 
isolates  MCPyV339 and MCPyV350 (Figure 9), the former of which is employed in 
most of MCPyV seroepidemiological studies including ours (115, 125, 126, 129). Though 
the known MCPyV isolates share as high as 99% of the amino acid sequences in their VP1 
regions, Kean et al. found in the general population a lower seroprevelence with 
MCPyV350 than with MCPyV339. They also observed as many as 164 sera to be IgG-
positive for VP1 of isolate 350 but not of isolate 339, whereas 560 sera were positive for 
isolate 339 but not 350, suggesting that between these two variants certain epitopes 
recognized by human sera are different (122). Carter et al. found that among MCC patients 
the seroprevalence and seroreactivity with MCPyV339 were significantly higher than with 
MCPyV350, implying that MCPyV339 may contain certain MCPyV VP1 epitopes not 
present in isolate 350 (122, 127). Thus, our studies do not reflect the precise MCPyV 
seroprevalence in Finnish population. It is plausible to expect some individuals harboring 
antibodies to certain epitopes of MCPyV isolates other than 339. Sequence alignment 
shows MCPyV339 and MCPyV350 differing in the VP1 regions by four amino acids, two 
of which are shown by mutagenic analysis to be critical for the epitopes present in 
MCPyV339 (127). Since BKPyV has four antigenic types, it will be worthwhile to know 
whether MCPyV isolates can be grouped into different serotypes (256, 257).  
2.2 Antigenic cross-reactivity between different HPyVs  
MCPyV and TSPyV VP1 have an overall amino acid similarity of approximately 50% to 
each other (6, 9, 258). In our competition assays, the VLPs of these two viruses did not 
compete with each other, demonstrating that in humans the majority of TSPyV and 
MCPyV antibodies are, at least in regards to the antibodies measured by these assays, 
species specific. A number of studies, either using as antigens VLPs or GST recombinant 
VP1 protein, have shown that antibodies against BKPyV and JCPyV do not cross-react 
with MCPyV (122, 124-126). Van der Meijden et al. showed that sera positive for TSPyV 
VP1 antibodies did not cross-react with MCPyV VP1 and BKPyV VP1 (245). Among the 
12 HPyVs, the VP1 amino acid similarity ranges from 25% between BKPyV and HPyV7 
to 78% between BKPyV and JCPyV (Figure 9) (258). However, seroepidemiological 
studies indicate cross-reactivity unlikely exists between antibodies against the HPyVs VP1 
(258). On the other hand, as the VP1 antibodies in human sera only recognize 
conformational epitopes, cross-reactivity might exist in the linear epitopes between 
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HPyVs with high VP1 homogeneity. Of note, in Western blot, hyperimmune rabbit serum 
against GST fused VP1 protein of BKPyV showed strong cross-reactivity with the VP1 of 
JCPyV, suggesting linear epitopes shared by these two viruses (250). The minor capsid 
proteins VP2 and VP3, as lining the interiors of HPyV particles, are thought to induce 
antibodies less frequently than VP1. Interestingly, Kantola et al. found that some human 
sera showed IgG reactivity with KIPyV and WUPyV VP2 and VP3 in Western blot. 
Moreover, they found cross-reactivity between these two viruses with regard to IgG for 
denatured VP2 and VP3 (259).  
 
Figure 9 Phylogenetic analysis of HPyVs VP1 protein sequences. Neighbour-joining tree was 
generated using online ClustalW2 programme 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Thirteen HPyVs sequences were 
obtained from Genbank. These included JCPyV (NC_001699), BKPyV (NC_001538), 
KIPyV (NC_009238), WUPyV (NC_009539), MCPyV 339 (EU375804), MCPyV 350 
(EU375803), HPyV6 (NC_014406), HPyV7 (NC_014407), TSPyV (NC_014361), 
HPyV9 (HQ696595), MWPyV (JQ898292), STLPyV (NC_020106), and HPyV12 
(JX308829) 
2.3 Asymptomatic MCPyV and TSPyV primary infections in childhood 
In Study III, we examined the clinical correlates of primary infections with MCPyV and 
TSPyV among the children followed over several years. With neither MCPyV nor TSPyV 
was the occurrence of symptoms or signs significantly associated with the time of 
seroconversion, suggesting that primary exposures to these viruses in childhood are 
asymptomatic. Similarly, Tolstov et al. neither found clinical associations of MCPyV 
primary infection among male adults (194). Upper respiratory tract infections, as expected, 
were the most frequent infections in Study III. However, their occurrence was not 
associated with MCPyV or TSPyV primary infections. In Study I, no MCPyV 
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seroconversions were found in children at the time of acute wheezing. Although MCPyV 
DNA has been found in respiratory tract samples (143, 146, 148), our observations rule 
against the involvement of MCPyV in respiratory tract infection. A similar conclusion has 
been reached with WUPyV and KIPyV, also discovered in respiratory samples (13, 14, 59, 
260). So far, there has been no firm evidence for an etiological role of any of the newly 
discovered polyomaviruses in respiratory illness.  
The prototypic HPyVs, BKPyV and JCPyV are known to establish a persistent, 
seemingly asymptomatic infection in immunocompetent individuals (261, 262). Although 
BKPyV seroconversion has been reported in a small number of children with clinical signs 
of acute upper respiratory tract infection, so far no solid evidence exists to link BKPyV to 
the disease (263). Different from the prior study which investigated BKPyV 
seroconversion in children with certain disease, our study investigated whether symptoms 
and signs of any infection-related illness in children were associated with viral 
seroconversion. We found primary infection with MCPyV and TSPyV in children to be 
asymptomatic. BKPyV and JCPyV can reactivate and lead to serious diseases such as 
PVAN and PML (46, 48). As the MCPyV and TSPyV-related diseases occur under 
immunosuppression, it is tempting to speculate that these viruses might persist long after 
primary infection and reactivate to pathogenicity. MCPyV is considered a member of our 
normal skin flora. Apparently, the virus, after encountering mutation and integration, can 
give rise to this rare cancer (7, 192). Previous studies showed that an active TSPyV 
infection was associated with TS pathogenesis (9, 10). However, our observation here 
rules against a connection between TSPyV primary infection and disease, and raise the 
possibility that the disease is due to TSPyV reactivation.  
Interestingly, exanthema, a common sign of skin infection, appeared in seven children 
(15.9%) at the MCPyV seroconversion interval but only in one child in the adjacent 
periods (2.2 % before, 2.3 % after), though the rate did not reach statistical significance, 
possibly due to small size of cohort. Since MCPyV and TSPyV are of skin tropism, it is 
possible that some skin-related signs beyond our interview were present in our cohort. In 
addition, infection-related symptoms might appear in geographic regions outside Finland. 
In the future, it could be worthwhile to investigate dermatological manifestations in larger-
size cohorts as well as in various geographic locations. 
3. Biotin IgM antibodies (IV) 
3.1 The effect of biotin IgM on biotinylation-associated EIAs  
For detecting anti-viral IgM antibodies, our laboratory, as many others, is using and also 
setting up µ-capture EIAs employing as antigen biotinylated VLPs detected by HRP-
conjugated streptavidin. With MCPyV IgM EIA, we employed as negative controls serum 
samples obtained from individuals with past immunity against MCPyV, and found one 
sample exhibiting strong reactivity in the assay. Interestingly, this sample showed IgM 
reactivity with the biotinylated MCPyV VLP but not with the corresponding 
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unbiotinylated VLP, suggesting that IgM antibodies in human blood cause false results in 
biotinylation-based antiviral IgM assays. The adverse effects of the biotin IgM on several 
antiviral IgM assays were then assessed. As expected, serum samples with high levels of 
biotin IgM affected adversely all five IgM assays of µ-capture format, whereas samples 
with low levels exhibited low interference with those assays. Furthermore, among the IgM 
assays for different viruses, the effects of biotin IgM differed and MCPyV IgM EIA was 
the most susceptible. The degree of adverse effects seemingly correlates to the 
conformation of viral particles or their degree of biotinylation. Therefore, two ways are 
proposed to limit the adverse effect. One is to use appropriate amount of biotin to label 
antigens, and the other is to employ a borderline zone upon setting up the cutoffs 
according to the false reactivity derived from biotin IgM. 
3.2 Potential origins of biotin IgM 
The origin of biotin IgM is an intriguing question. Existing reports on occurrence of 
human antibodies to vitamins are scarce. Vitamin D IgG antibodies were present at a low 
prevalence in patients with autoimmune diseases (264). For the biotin IgM we found a 
seroprevalence of 3% among Finnish adults. This prevalence is quite close to those of 
some known autoantibodies among the general population, e.g. 1-3% of rheumatoid factor 
(265-267). It is possible that the biotin IgM antibodies are related to autoimmunity. 
Secondly, in the human blood, biotin only accounts for half the total avidin-binding 
substances, and biotin metabolites account for the rest (268). It is possible that some 
imbalance in biotin metabolism will induce an immune response to these biotin 
metabolites, resulting in the generation of biotin antibody. Thirdly, in Study IV the affinity 
levels of biotin IgM ranged from 10
-3
-10
-4
 mol/L, close to that of many polyreactive 
antibodies generated without known antigenic stimulation (269-272). Polyreactive 
antibodies generally belong to the IgM class and target endogenous host antigens (269-
272). As biotin can interact with host proteins, biotin IgM might be a group of 
polyreactive antibodies induced by the biotin-host complexes (273-275). 
3.3 Possible clinical biomedical effects of biotin IgM 
Biotin acting as a coenzyme is essential for in most organisms, and catalyzes critical 
reactions in the intermediary metabolism of gluconeogenesis, fatty acid synthesis, and 
amino acid catabolism (274). Biotin deficiency can lead to a number of clinical 
abnormalities, such as hair loss, growth retardation, neurological disorders and 
vulnerability to infections (276, 277). The avidin in raw eggs binds biotin and prevents its 
intestinal absorption, so biotin deficiency can ensue in persons excessively consuming raw 
eggs (278-280). After intestinal absorption, biotin circulates in the human blood for uptake 
by cells (273). We showed that biotin IgM and streptavidin/avidin share the same binding 
site on biotin. It is possible that biotin IgM in blood will function as avidin in the intestinal 
tract, preventing biotin uptake by tissues and cells. This assumption indeed deserves 
further investigation. 
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CONCLUSIONS AND FUTURE PROSPECTIVES 
This thesis includes studies on the two recently detected human polyomaviruses MCPyV 
and TSPyV, with respect to (i) development of serodiagnostic assays, (ii) determination of 
their seroepidemiology among Finnish cohorts, and (iii) identification of possible clinical 
pictures associated with primary infections in childhood. In addition, the thesis aims at 
improving the quality of antiviral IgM assays, and identifies and characterize endogenous 
biotin IgM antibodies circulating in our blood. 
In the thesis, MCPyV and TSPyV VP1 proteins were readily expressed in the 
baculovirus system and self-assembled into virus like particles. Using VLPs as antigen, 
we developed for MCPyV and TSPyV comprehensive diagnostic assays including EIAs 
for IgG, IgM and IgG avidity, for estimation of MCPyV and TSPyV primary infections. 
We found with the two viruses high seroprevalence rates among adults, and high rates of 
primary infections among children, implying that MCPyV and TSPyV circulate widely 
among the general population, in particular during early childhood. In a longitudinal study, 
comparing the seroconversion intervals with the previous and subsequent intervals for 
clinical events, we found the primary infections by neither virus to be significantly 
associated with symptoms or signs of any infection-related illness, indicating that these 
pathogenic polyomaviruses circulate silently among constitutionally healthy children. 
With MCPyV and TSPyV, future studies may aim at addressing the following issues. 
Firstly, MCPyV and TSPyV apparently are capable to enter latency and later reactivate. 
Thus, the persistence sites and patterns, reactivation mechanisms, as well as reactivation-
related diseases other than MCC and TS, are calling for further investigation. Secondly, 
these two viruses have been shown to be associated with human skin diseases  MCPyV 
with MCC and TSPyV with TS. Therefore, it is worthwhile to know whether these viruses 
can serve as markers in diagnosis of their related diseases or as targets for treatment. 
Thirdly, since at least two MCPyV variants have been found, it will be interesting to know 
with MCPyV and TSPyV whether any other variants exist, and whether the pathogenicity 
differs among variants. In addition, since ten HPyVs have been discovered by novel 
detection methods during the past six years, one could expect more such viruses that 
silently circulate in the general population, to be discovered in the future. 
Presence of IgM antibodies to biotin in some human sera has been accidentally found 
during thorough evaluation of the described serodiagnostic assays. These antibodies 
adversely affect a variety of biotinylation-based antiviral IgM assays, causing false-
positive results for viral IgM. The prevalence of biotin IgM was 3% among adults, close to 
the prevalence of the rheumatoid factor autoimmune antibody. However, the affinity of 
biotin IgM was at a range close to that of polyreactive antibodies. The biotin IgM and 
streptavidin were found to share the same binding site on biotin. These findings provide 
new insights into biotinylation-based immunoassays and new information on the immune 
recognition of vitamins.  
Thus, several aspects deserve further investigations. (i) The origin of biotin IgM. These 
antibodies may originate from an autoimmune process or may represent a group of 
polyreactive antibodies. (ii) The biomedical effects of biotin IgM. Biotin IgM might 
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inhibit the uptake of biotin from circulation, or might keep the balance of biotin with its 
metabolites in blood. Occurrence of biotin IgM might prevail in certain risk groups, e.g. 
patients in context of biotin deficiency. (iii) The side effects of biotin IgM on serological 
assays. As biotinylation is widely employed in serological assays, in addition to antiviral 
IgM assays these antibodies might affect a variety of biotinylation-based immunoassays. 
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